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Abstract 
 
Phosphoenolpyruvate carboxykinase (PEPCK) catalyses a reaction that is known to be 
thermodynamically reversible. In contrast to this thermodynamic reversibility, in eukaryotes, PEPCK is 
observed to primarily catalyze the forward direction, converting oxaloacetic acid to phosphoenolpyruvate 
as one of the principle steps in gluconeogenesis. Based upon these seemingly conflicting pieces of data, 
we hypothesize that there must be an underlying mechanism regulating the kinetic reversibility of the 
catalyzed reaction in vivo.  
To this end, we present structural and kinetic evidence for the presence of an allosteric site in PEPCK, 
which we propose binds negatively charged ions such as chloride which is found in abundance in vivo. 
This allosteric regulation serves to inhibit catalysis in the reverse direction and contribute to the observed 
unidirectionality in the direction of PEP synthesis in vivo. As supporting evidence for this hypothesis, we 
have collected anomalous diffraction data on several PEPCK crystals that have been exposed to a range of 
iodide concentrations. From the corresponding anomalous signals at each concentration, we were able to 
analyze anomalous peak heights and generate binding isotherms for various anion binding sites on 
PEPCK. Importantly, one of these anion binding sites was observed to titrate with increasing iodide 
concentration, yielding an apparent binding constant similar to that obtained from our kinetic inhibition 
studies. This site was in contrast to the others which were shown to not titrate over the same range of 
iodide concentrations. 
The anomalous data in combination with the kinetic data were essential in assigning the allosteric 
mechanism of regulation as the origin of the observed inhibition. This result was in contrast to 
preliminary anomalous maps calculated at saturating concentrations of iodide which suggested anions 
binding to the active site in a purely competitive fashion. This allosteric mechanism of inhibition was 
further validated through additional anomalous diffraction and kinetic studies on three mutant enzyme 
variants, giving strong support for the proposed mechanism of regulation, an effect that has interesting 
biological ramifications for the in vivo functioning of PEPCK. 
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Chapter 1: Introduction 
1.0 Background of PEPCK 
Glucose metabolism is tightly regulated through two distinct metabolic pathways that are not simply the 
reverse of one another, but act to achieve opposite goals – the breakdown of glucose or the generation of 
glucose (Figure 1). The catabolic pathway, known as glycolysis, begins in the cytosol with glucose 
gradually being broken down into a smaller molecule, pyruvate, by a series of glycolytic enzymes through 
several intermediate reactions. Pyruvate is then converted to acetyl-CoA and then to citrate as it cycles 
through the citric acid cycle (located in the mitochondria), generating ATP as a source of biochemical 
energy to be used by the cell.1 
The anabolic pathway, or gluconeogenesis, is one of the pathways responsible for replenishing the body’s 
energy storage. Through a series of enzymatic reactions, pyruvate is converted into glucose. Similar to 
glycolysis, the majority of the gluconeogenic pathway occurs in the cytosol, with the exception of the first 
few steps. In eukaryotes, the conversion of pyruvate to oxaloacetate (OAA) occurs within the 
mitochondria, while the enzymes needed to catalyze the reactions from phosphoenolpyruvate (PEP) 
onwards are located in the cytosol.1 The enzyme that catalyzes the formation of PEP from OAA is 
phosphoenolpyruvate carboxykinase. 
 
 
 
 
 
 
Figure 1: Simplified reaction map of glucose metabolism in the cell. Glycolytic and gluconeogenic reactions, labelled 
in orange and blue respectively, occur partially in both the mitochondrial matrix (left) and the cytosol (right).  Pyruvate 
crosses the mitochondrial membrane via specialized transport proteins shown as a green cylinder. 
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Phosphoenolpyruvate carboxykinase (EC 4.1.1.32), known by its acronym PEPCK, is a key enzyme in 
the regulation of glucose metabolism. In most higher eukaryotes, PEPCK catalyzes the reaction of 
oxaloacetic acid (OAA) to phosphoenolpyruvate (PEP), by using guanosine triphosphate (GTP) as a 
phosphoryl donor. 
 
Figure 2: PEPCK-catalyzed reaction. A diagram of the PEPCK-catalyzed reaction, written in from 
left to right in the physiological direction of gluconeogenesis. The GTP/GDP nucleotide structure is 
not shown. 
 
It is of interest to note that some prokaryotic organisms and other eukaryotes, including fungi and plants, 
use adenosine triphosphate (ATP) or even pyrophosphate (PPi) as a source of phosphate instead.2 To 
further complicate things, PEPCK can be further divided into cytosolic and mitochondrial isoforms 
known as cPEPCK and mPEPCK respectively.3 
mPEPCK is the lesser understood of the two PEPCK isoforms, and not much is known mechanistically 
aside from that fact that mPEPCK’s structure is nearly identical to that of cytosolic PEPCK, with high 
sequence conservation. cPEPCK is well studied and is known for its integral role in gluconeogenesis and 
glyceroneogenesis, as well as its more recently discovered role as a cataplerotic enzyme involved in the 
recycling of amino acid skeletons.4,5 It was previously thought that regulation of PEPCK and its role in 
glucose metabolism could be attributed to changes in gene expression as it has been demonstrated that 
transcription of the PEPCK gene is stimulated by cyclic AMP and the hormone glucagon and inhibited by 
insulin.6–8 More recent research however, suggests control of PEPCK at the protein level, involving 
posttranslational crosstalk of acetylation, ubiquitination and phosphorylation of PEPCK contributing to 
the regulation of cataplerotic versus anaplerotic reactions.9,10  
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Although PEPCK primarily catalyzes the reaction of OAA to PEP, the PEPCK-catalyzed reaction is 
actually thermodynamically reversible, in that the reaction can proceed in either direction.11 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Reaction coordinates for the PEPCK-catalyzed reaction. A diagram 
showing the thermodynamic reversibility of the PEPCK-catalyzed reaction.11  
 
This phenomenon of thermodynamic reversibility seemingly conflicts with the earlier statement that C-
PEPCK unidirectionally catalyzes the OAA→PEP reaction, which we can call the forward direction, or 
the physiological direction necessary for gluconeogenesis.  
Standard kinetic assays for PEPCK activity demonstrate this reaction reversibility in vitro. Given the ideal 
conditions needed to optimize activity, cPEPCK is able to catalyze the conversion of PEP to OAA, albeit 
with a lower maximum activity when compared to a standard activity assay performed in the forward 
direction.12 
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Table 1: Kinetic parameters for the PEPCK-catalyzed reaction in vitro.12 
 kcat (s-1) kcat/KM (M
-1 s-1) 
(OAA/PEP) 
kcat/KM (M-1 s-1) 
(GTP/GDP) 
OAA → PEP 52 ± 1 1.0 x 106 9.5 x 106 
PEP → OAA 19 ± 1 3.7 x 104 9.2 x 104 
 
Previous kinetic studies trying to determine the reason behind lower enzyme activity in the reverse 
direction have focused on the required carbon dioxide (CO2) substrate. After assaying for enzyme activity 
at high concentrations of CO2, it was concluded that there was substrate-mediated inhibition (Figure 4).13 
 
 
 
 
 
 
 
 
 
Figure 4: Substrate-mediated inhibition of PEPCK. Apparent 
inhibition of PEPCK activity at high concentrations of KHCO3, the 
source of CO2 in vitro.  
 
However, our recent research suggests that this observed inhibition is not substrate-mediated, but rather 
due to the anionic nature of the dissolved bicarbonate anion, a source of CO2 but not PEPCK’s true 
substrate. 
  
Figure 5: Equilibrium of dissolved bicarbonate in water. A schematic of 
bicarbonate ion dissolved in water. By bubbling in gaseous CO2, you can shift 
the equilibrium towards PEPCK’s true substrate. 
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Investigation into the potential regulatory properties of anions is necessary in order to determine the 
underlying cause behind the unidirectionality of the PEPCK-catalyzed reaction in vivo. It is important to 
note that through the optimization of standard activity assays in vitro, the majority of salts that would be 
found in biological systems are removed. It is therefore accurate to say that cPEPCK would be subjected 
to much higher concentrations of various anionic species in vivo, which could have an adverse effect on 
enzyme function. 
 
1.1 Enzyme Kinetics 
In order to understand the effects of anionic inhibition, the enzyme kinetics of the PEPCK-catalyzed 
reaction must be analyzed. Enzyme kinetics refers to the study of reaction rates and substrate-binding 
affinities, as well as inhibitory effects on reaction rate and enzyme turnover. The reaction rate, denoted by 
the symbol ν, can be plotted against substrate concentration [S] to generate a plot with a distinct 
hyperbolic shape (Figure 6). This plot is called a Michaelis-Menten curve, named after two scientists who 
made significant contributions to enzyme kinetics.14 
 
Figure 6: A basic Michaelis-Menten curve. The plot represents the rate of enzyme 
catalysis, ν, as a function of substrate concentration, [S]. From this plot, the 
Michaelis-Menten constant, or KM, can be derived as the substrate concentration at 
one half Vmax. 
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Michaelis-Menten kinetics allows us to determine the maximum reaction rate, Vmax, and the Michaelis-
Menten constant, or KM. The KM can be calculated as the substrate concentration at half the Vmax, 
representing the enzyme’s affinity for that particular substrate. However, this is often only an apparent 
affinity, as many other factors affect the KM, and may be masking the true binding affinity of the substrate 
to the enzyme. A more accurate definition of the Michaelis constant is the concentration of substrate at 
which the time required for substrate capture is equal to the time for product release.15 The addition of an 
inhibitor can affect both the Vmax and the KM, depending on the type of inhibition and mechanism of 
inhibitor binding.16 
Enzyme inhibition can be categorized into three different classes: competitive, uncompetitive, or mixed 
inhibition, which is sometimes referred to as non-competitive inhibition in certain cases where the 
inhibitor can bind equally to the enzyme or enzyme-substrate complex. Inhibitors are classified into these 
different groups by the mechanism in which they interact with the enzyme or enzyme-substrate complex 
(Figure 7).  
Competitive inhibitors only bind to free enzyme without substrate bound, lowering the apparent substrate 
affinity or KM while leaving the overall reaction rate (Vmax) unchanged.1 The effect on apparent KM 
requires adding additional substrate to the assay mix to ensure saturating substrate concentrations. 
Uncompetitive inhibitors bind to the enzyme-substrate complex, due to a conformational change that 
occurs upon the substrate binding, therefore adding additional substrate has no effect. Both the apparent 
Vmax and KM are affected. Mixed inhibitors have the properties of both competitive and uncompetitive 
inhibition, in that the inhibitor binds to both the free enzyme and the enzyme-substrate complex.1  
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Figure 7: Types of enzyme inhibition classified by enzyme-inhibitor interactions. 
Uncompetitive inhibitors can be allosteric in nature, meaning they only bind to the enzyme at a secondary 
site away from the catalytic active site. Competitive inhibitors generally bind at the active site where 
substrates would bind, but can also act in an allosteric fashion, provided the enzyme-inhibitor complex 
does not allow for substrate binding.  
The term ‘allosteric’ was first coined in 1961 from the prefix ‘-allo’ meaning ‘other’ and ‘steric’ referring 
to the spatial arrangement of a molecule.17 In other words, allostery refers to a mechanism of binding 
where the inhibitor is not a steric analogue of the substrate. Allosteric binding was historically understood 
to occur in multimeric enzymes, where binding to one subunit would cause a conformational change 
affecting the activity of the entire enzyme. Today allostery is also understood to occur in monomeric 
enzymes, and recent research has suggested that allosteric binding may occur without an observable 
conformational change, due to the intrinsic dynamic nature of proteins.18,19 Allosteric binding can be 
either inhibitory or activating in nature, and can be thought of as an ON/OFF switch. 
Enzymes that are controlled by allosteric regulation are classified as either K-type, if the allosteric 
effector alters the KM for the substrate, or V-type, if there is a change in their maximum enzyme activity. 
Most allosteric enzymes are K-type: binding of an effector to the allosteric site causes a conformational 
change resulting in an apparent change in affinity for the substrate at a different site.20 
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Multiple kinetic studies have already shown various different types of substrate-analogues can act as 
competitive inhibitors of cPEPCK and related enzymes.21,22 Only a few allosteric inhibitors of PEPCK 
have been identified, including 3-mercaptopicolinate, previously identified only as an active site 
inhibitor.23–25 Michaelis-Menten curves can be used to show the various forms of enzyme inhibition, in 
this case competitive inhibition. Through a series of kinetic inhibition assays, an inhibition constant, or 
KI, can be calculated, which is a representation of the inhibition strength of that compound. An inverse 
relationship exists between the KI and the strength of the inhibitor, such that the lower the KI, the stronger 
the inhibitor and vice versa. 
For this study on the regulation of PEPCK activity, enzyme inhibition can be studied kinetically using 
simple halides to represent the anionic conditions of the intracellular environment. Chloride is one of the 
most prevalent anions in a biological system, ranging from 10 mM up to 100 mM or higher, depending on 
the type of cell and organism.26,27 Inhibition of PEPCK can be examined by performing an activity assay 
under increasing chloride concentrations, to mimic the physiological conditions found in vivo. Such 
inhibition assays can be performed in the ‘forward’ or physiological direction of catalysis by adding OAA 
and GTP substrates (Figure 8a). Similarly, inhibition of the ‘reverse’ direction of catalysis can be 
analyzed by adding PEP and GDP to the kinetic assay (Figure 8b). 
a) Forward Direction 
OAA + GTP → PEP + CO2 + GDP 
b) Reverse Direction 
PEP + CO2 + GDP → OAA + GTP 
Figure 8: Directional PEPCK-catalyzed reactions. The PEPCK-catalyzed reaction is 
written as separate unidirectional reactions. The “forward” direction corresponds to the 
physiological direction of gluconeogenesis in biological systems, while the “reverse” 
direction is only observed in kinetic assays performed in vitro.  
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1.2 X-ray Crystallography 
Enzyme function can also be analyzed through a structural approach, using protein crystallography. 
Crystallography involves the growth of protein crystals large enough to be viewed under a microscope, 
ideally a couple hundred microns (µm) in length. Growing crystals is a delicate process typically 
performed using vapour diffusion to achieve a slow and gradual removal of water from the protein 
sample, moving from soluble to crystalline on the protein solubility curve without causing the protein to 
precipitate out of solution. 
The resulting crystal consists of millions of protein subunits stacked together in such a structure that has 
different axes of symmetry depending on the type of crystal packing. The simplest repeating unit in the 
crystal structure is called the Unit Cell, which is stacked in three dimensions to form the macroscopic 
crystal. Even smaller still is the aptly named Asymmetric Unit, or ASU, the smallest repeating component 
of the crystal which can contain one or more protein subunit. Applying symmetry operations to the ASU 
generates the unit cell (Figure 9).28 
 
 
 
 
 
 
Figure 9: Assembly of unit cells into a complete crystal structure. Asymmetric units are shown as blue triangles and 
unit cells are shown as cubes. 
 
Crystal Lattice Unit Cell 
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To analyze protein structure, we can use a technique involving X-ray Diffraction. By subjecting a crystal 
to X-rays, the incident beam will diffract through the crystal, interacting with the electrons that comprise 
the different atoms of the peptide structure. The crystal itself acts as an amplifier to increase the 
diffraction signal picked up by the detector on the other side of the mounted crystal. The detector 
measures a series of spots or reflections that represent diffracted x-rays that are in-phase with each other, 
resulting in constructive interference. The resulting diffraction pattern of spots (Figure 10) gives us the 
intensity of the diffracted x-rays, dependent upon the exposure time the crystal is subjected to. 
 
Figure 10: Example of a series of spots that make up an x-ray diffraction pattern. 
Multiple high-resolution images taken at 360° around the crystal make up a 
complete dataset that must be indexed, integrated and scaled. Resolution in Å is 
denoted by red circles, with high resolution data in the corners. 
At this point, only the X-ray amplitudes are known, but in order to determine electron density of the 
atoms in the protein crystal, the phase information of the diffracted X-rays is required. Molecular 
replacement is a common technique that uses another crystal structure with sufficient homology to that of 
the protein structure being studied to obtain the phases.29 Using the obtained phase information combined 
with the intensities from the diffraction pattern, we can generate electron density maps and fit amino acid 
residues to the electron density, provided we know the primary sequence of our protein. 
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When trying to solve a new crystal structure, often the PDB database will not contain any structures with 
sufficient homology to the protein being studied. In this case, molecular replacement is not an option, and 
another solution to the phase problem must be determined. 
A specialized technique using isomorphous replacement followed by multi-wavelength (MAD) or single-
wavelength anomalous diffraction (SAD) is another solution sometimes used to obtain phase 
information.30–33 Isomorphous replacement involves the addition of heavy atoms to the protein crystal, 
often through soaking experiments. Anomalous diffraction or anomalous scattering is a phenomenon that 
occurs when an atom is hit with enough energy to excite one of its electrons, causing it to transition into a 
higher energy electron shell. When the electron returns to its original shell, it releases the energy with a 
phase shift compared to that of the incident X-rays (Figure 11). The wavelength at which the energy 
corresponds with an atom’s ionization potential is known as an absorption edge, a sharp spike in that 
atom’s absorption spectrum. From the anomalous phases and the intensities of the diffracted X-rays, the 
electron densities can be determined. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: A schematic showing anomalous scattering of X-rays. Anomalous dispersion of x-rays occurs when the 
wavelength of the incident beam (shown in black) corresponds with the energy of the K, L or M shells (labelled and 
coloured black, red and blue respectively). The energy absorbed by an electron causes it to excite to a higher shell, 
eventually releasing the energy (shown in orange) and falling back to its original shell. 
 
 
 
Scattered X-ray 
Incident X-ray 
K 
L 
M 
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1.3 PEPCK Crystal Structure 
The structure of rat cytosolic PEPCK, the isoform of PEPCK that we study in the lab, is already well 
characterized, and its structure with several ligands bound can be found on the PDB database. rcPEPCK is 
a 622 amino acid monomer with a globular structure, with 3 dynamic loops involved with catalytic 
function found at the enzyme’s active site (Figure 12).34 One of the aforementioned loops, the Ω-loop, is 
named for its characteristic fold in the distinct shape of the Greek omega symbol. It acts as a lid to protect 
reaction intermediates from unwanted chemistry, and is thus sometimes referred to as the Ω-loop lid.35 
The other two loops found within the active site are the P- and R-loops, responsible for the coordination 
and positioning of the GTP/GDP nucleotide and the OAA/PEP substrates respectively.36 
 
Figure 12: Ribbon structure of PEPCK’s active site. PDB ID: 2QEW. The catalytically active loops, 
the R-loop and the P-loop, are labelled and coloured yellow and pink respectively. A single M1 
manganese cation is labelled and depicted as a small grey sphere. All graphics were generated using 
CCP4MG.37 
 
The P- and R-loops undergo conformational changes necessary for enzyme catalysis upon substrate 
binding.36 This transition from a disordered to an ordered state is what allows the reaction to proceed, and 
any extrinsic force that prevents this transition negatively affects enzyme function.  
Mn
2+
 P loop 
R loop 
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1.4 Structural and Kinetic Analysis of PEPCK Regulation 
Now that the two different approaches of enzyme characterization have been introduced, we can proceed 
to ask the question: although thermodynamically reversible, what factors may contribute to the typically 
observed unidirectionality of the PEPCK-catalyzed reaction in vivo? Our objective is to use a combined 
structural and kinetic approach to determine the possibility of the regulation of PEPCK activity in vivo by 
anions. 
From kinetic data found in the literature, as well as previous kinetic assays done in our lab38,39, it can be 
observed that PEPCK is catalytically active in both directions in vitro, which seemingly conflicts the 
aforementioned statement that only the “forward” direction is catalyzed in biological systems. 
Interestingly, although kinetic assays performed in the lab indeed show activity in the “reverse” direction, 
the maximum rate of catalysis is significantly lower, roughly by a factor of two when compared to assays 
performed in the “forward” or physiological direction of catalysis.12 
From the aforementioned study13, we hypothesized that anionic inhibition was occurring in the reverse 
direction of catalysis, leading to the observed decrease in reaction rate in that direction. Logically, this 
inhibitory effect would be greater in vivo, where PEPCK is subjected to higher concentrations of salts. 
Chloride is an obvious choice to study enzyme inhibition in vitro, due to its physiological relevance and 
abundance in biological systems. 
For a structural approach, iodide was chosen as the inhibitor instead of chloride, due to its unique 
anomalous properties (Table 2). Of all of the halides we had at our disposal in the laboratory, iodide has 
the closest absorption edge to the wavelength generated by our home source’s rotating copper anode 
(CuKα = 1.54Å). Iodide has an absorption edge around 2.4Å, or 5.2 keV, corresponding to its L-I shell.40 
Based on these intrinsic properties, we can use single-wavelength anomalous dispersion (SAD) to detect 
where iodide, as our anionic inhibitor, is binding to PEPCK. 
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Table 2: Absorption edges of various halides.40 
X-ray Absorption Edge 
Iodine 
keV Å 
X-ray Absorption Edge 
Bromine 
keV Å 
K 33.1694 0.3738 K 13.4737 0.9202 
L – I  5.1881 2.3898 L – I  1.7820 6.9576 
L – II 4.8521 2.5553 L – II 1.5960 7.7684 
L – III 4.5571 2.7207 L – III 1.5499 7.9995 
M 1.0721 11.5646 X-ray Absorption Edge 
Chlorine 
keV Å 
CuKα 8.0509 keV 1.54 Å K 2.8224 4.3929 
Data was generated using the web-form at http://skuld.bmsc.washington.edu/scatter/AS_form.html. 
 
Figure 13: Absorption edge plot of common halides. The absorption spectrum of chlorine (purple), iodine (green) 
and bromine (blue), showing their various absorption edges, as well as the wavelength of the CuKα home source. 
The edge plot was generated using the web-form at http://skuld.bmsc.washington.edu/scatter/AS_form.html. 
 
Combining the data from the kinetic assays with the structural information obtained using X-ray 
crystallography and anomalous diffraction, we can demonstrate how PEPCK is regulated to catalyze the 
OAA to PEP reaction in a unidirectional manner in biological systems. In this way, we can provide 
evidence for how the cellular environment may affect regulation of metabolic pathways at a structure-
function level.
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Chapter 2: Experimental Procedures  
2.1 Materials 
GDP and ADP were purchased from Combi Blocks and BioShop respectively. GTP, PEP, and NADH 
were purchased from Chem-Impex International, and OAA was purchased from Millipore Sigma 
(CalBioChem). Co-NTA resin was purchased from UBP Bio and regenerated in the laboratory as Ni-NTA 
resin. P6DG and Chelex resin were purchased from BioRad. TCEP and DTT reducing agents were 
purchased from GoldBio. 
2.2 Enzymes 
The enzymes used in the coupled-enzyme assay for PEPCK activity, pyruvate kinase, lactate 
dehydrogenase and malate dehydrogenase, were used as provided by the supplier (Calzyme). The plasmid 
expressing His6-SUMO protease was a gift from C. Lima (Sloan-Kettering Institute, New York, NY). The 
SUMO protease was expressed and purified via the protocol below. 
A 50 mL culture of BL21 E. coli cells containing the His6-SUMO plasmid was grown overnight at 37°C 
and 225 rpm in LB media containing 50 µL of 50 mg/mL kanamycin. The overnight culture was added to 
inoculate 1L of fresh LB-Kan media. The culture was incubated at 37°C until the OD600 reached 2.0. The 
incubation temperature was lowered to 30°C and expression was induced by adding IPTG to a final 
concentration of 0.75 mM (10 mL of 75 mM IPTG). Cells continued to grow under these conditions for 
an additional 4 hours, then were spun down at 6000 rpm, room temperature for 15 minutes. The 
supernatant was discarded and the resulting cell pellet was resuspended in buffer containing 25 mM 
HEPES pH 8.0, 350 mM NaCl, 2 mM TCEP and 20 mM imidazole. The resuspended cells were lysed via 
two passes through a French Press, then centrifuged at 12 000 x g for 30 minutes at 4°C. The pellet was 
discarded and the supernatant was incubated for 1 hour at 4°C with Ni-NTA resin that had been pre-
equilibrated with the same resuspension buffer. The Ni-NTA resin was washed with buffer until the flow 
through reached an A280 < 0.1. The SUMO protease was then eluted from the resin using an elution buffer 
containing 25 mM HEPES pH 8.0, 350 mM NaCl, 2 mM TCEP and 400 mM imidazole. The eluate was 
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concentrated to 5 mg/mL (ε280 = 1.18 mL mg-1) and 50% glycerol was added to a final volume of 25% 
(v/v). The final protease solution (2.5 mg/mL) was flash-frozen in small aliquots by immersion in liquid 
nitrogen and stored at -80°C. 
 
2.3 Cloning and transformation of the WT rcPEPCK DNA sequence into an expression 
vector 
The gene encoding for WT rat cytosolic PEPCK was cloned into a pSUMO-star expression vector as 
previously described.35 The entire plasmid was then subsequently transformed using heat shock into the 
BL21 E. coli cell line, and stored at -80°C as a common laboratory cell stock.  
The WT rcPEPCK plasmid was purified using a High-Speed Plasmid Mini Kit by Geneaid. The miniprep 
protocol was followed as provided by the supplier, and the purified plasmid was stored at -20°C. The 
purified plasmid was used as the template sequence for PCR mutagenesis. 
 
2.4 PCR mutagenesis of rcPEPCK 
Forward and reverse primers were designed to introduce the F284H and F284W mutations into the 
PEPCK DNA sequence. An E. coli codon usage chart was used to determine the ideal single-base pair 
substitution to mutate the phenylalanine residue at position 284 into a histidine or a tryptophan. The 
resultant mutant DNA primers were subsequently synthesized by Sigma-Genosys (Table 3).  
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Table 3: Mutant Primer Design for F284H and F284W rcPEPCK enzyme variants* 
Primer Name Length (nt.) Tm (°C) 
t993c_t994a forward 27 79.46 
t993c_t994a reverse 27 79.46 
Mutation 
 
F284H 
Primer Name Length (nt.) Tm (°C) 
t994g_c995g forward 27 79.46 
t994g_c995g reverse 27 79.46 
Mutation 
 
F284W 
*The codons in blue represent the changes in the wildtype DNA sequence for mutagenesis. 
PCR mutagenesis was performed using 1 µL of each of the mutant primers at 100 ng/µL, 0.5 µL of 
Phusion high fidelity polymerase (Thermo Scientific), 5 µL of dNTPs, 10 µL of 5X reaction buffer 
(Thermo Scientific), and 5 µL the WT PEPCK SUMOstar expression vector (100 ng/ µL) as the DNA 
template. The thermocycler parameters were set as shown in Table 4. After amplification, the PCR 
products were digested with Dpn1 for 1 hour to degrade the WT plasmid template. 
Table: 4: Cycling Parameters for PCR Mutagenesis 
Segment Cycle No. Temperature Time 
1 1 95°C 1 min 
2 1 95°C 30 s 
3 1 60°C* 1 min 
4 1 72°C 8 min 30 s 
5 2-18 Repeat segment 2 - 4 
6 18 72°C 10 min 
7 18 4°C HOLD 
*The annealing temperature was set as a gradient with an average temperature of 60°C ± 5°C. 
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The PCR products were run on an agarose gel to confirm successful DNA amplification, then transformed 
into chemically-competent XL1 E. coli cells via heat shock.41,42 The resultant cell culture was plated onto 
LB-Kanamycin agar plates using the streak-plate method. Colonies that successfully grew on the 
kanamycin plates were harvested and used to inoculate new LB-Kan media, and stored at -80°C as mutant 
PEPCK cell stocks. The mutant rcPEPCK plasmids were miniprepped using the same procedure as the 
WT plasmid miniprep, then sent to Robarts Research (London, ON, Canada) for sequencing to confirm 
the mutation of the corresponding codons and absence of unintended mutation of the remaining gene. 
 
2.5 Wildtype and Mutant rcPEPCK expression and purification 
The cell stock of BL21 E. coli containing the expression vector was used to inoculate four Erlenmeyer 
flasks of 50mL of LB-kanamycin media, which were left to incubate at 37°C while mixing overnight. The 
culture flasks were then each added to four separate flasks of 950mL autoinduction media, for a total of 
4L culture volume. The autoinduction media contains 50 µg/mL of kanamycin for antibiotic selection of 
pSUMO-star-containing cells. Autoinduction media also contains MgSO4, NPS salts, trace elements, 
glucose and lactose sugars for induction of the T7 lac promoter on the expression vector.43 The 
autoinduction flasks were incubated for 20-24 hrs at 20°C to induce expression of the His6-SUMO-
rcPEPCK fusion protein. 
The autoinduction media was then centrifuged at RT, 5000 x g for 15 minutes and the supernatant was 
discarded. The resulting cell pellet was resuspended in wash buffer containing 10% glycerol, 300 mM 
NaCl, 10 mM imidazole, 25 mM HEPES pH 7.5, and 2 mM TCEP-HCl. The resuspended cells were then 
lysed via two passes through a French Press, then spun down at 4°C, 12 000 x g for 1 hour. All protein 
purification from this point onwards was performed at 4°C. The protein-containing supernatant was added 
to Ni-NTA affinity resin that had been pre-equilibrated with 200 mL of wash buffer, and incubated with 
gentle shaking for a minimum of 1 hour.  
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After incubation, the Ni-NTA column was washed with approximately 600 mL of wash buffer to remove 
non-specifically bound proteins, until the flow-through reached an A280 of zero. At this point, the fusion 
protein was eluted off the column and collected in 10 mL aliquots (Figure 14), using an elution buffer 
composed of 300 mM imidazole, 25 mM HEPES pH 7.5, and 2 mM TCEP-HCl. Aliquots with an A280 > 
0.3 were then pooled together and concentrated to a final volume less than 10 mL via a 30 kDa filter and 
N2 gas concentrator. The concentrated eluate was added to a P6DG resin SEC column for buffer exchange 
that was pre-equilibrated with a second wash buffer containing 25 mM HEPES pH 7.5 and 2 mM TCEP-
HCl. The P6DG column was washed while collecting aliquots of 10 mL (Figure 14). Aliquots with an 
A280 > 0.1 were pooled together and SUMO protease was added to cleave the His6-SUMO tag from the 
fusion protein. The SUMO digest was left at 4°C with gentle mixing overnight. 
 
Figure 14: Nickel Affinity (left) and Size-Exclusion (right) chromatography columns for protein purification. 
Chromatography columns are equilibrated with buffer and then incubated with cell lysate containing the protein of 
interest. The His6-SUMO-PEPCK fusion protein binds to the Ni-NTA column and is eluted from the column after 
several washes. The SEC column is used for buffer exchange between steps. Incubating the protein eluate with SUMO 
protease removes the His6-SUMO tag so the protein can be concentrated and flash-frozen in liquid N2. 
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The SUMO-digested sample was then added to the Ni-NTA column, pre-equilibrated with 200 mL of 
wash buffer. The protein sample flowed through the column while the cleaved His6-SUMO tag remained 
bound to the column. Aliquots of 10 mL were collected once more, pooled together if A280 > 0.1, and 
concentrated to a final volume of less than 10 mL via a 30 kDa filter and N2 gas concentrator. The 
concentrated protein sample was added to a P6DG resin SEC column that had been pre-equilibrated with 
the final buffer, containing 25 mM HEPES pH 7.5 and 10 mM DTT for long-term stability and storage of 
the protein at -80°C. Aliquots containing protein were collected from the P6DG column, pooled together 
if A280 > 0.1, and concentrated to a final concentration of 10 mg/mL via 30 kDa filter centrifugation at 
4°C, 3500 x g, at 10 minute intervals. Protein concentration was determined using a NanoDrop 
spectrophotometer and an ε280 = 1.7 mL mg-1, using the final storage buffer as a blank. 
The final concentrated rcPEPCK sample was flash-frozen into 25 µL aliquots by pipetting directly into a 
liquid nitrogen-containing vial, and then storing the entire sample (roughly 1 to 1.5 mL total volume) at -
80°C, leaving the nitrogen to evaporate overnight. 
 
Figure 15: SDS-PAGE results for a representative WT rcPEPCK protein purification. 25 µL of sample was taken 
after each step of the purification protocol and loaded onto a 12% SDS PAGE gel after adding Coomassie Brilliant 
Blue dye. The total protein sample has been diluted 1/50, and the P6DG and SUMO digest samples were overloaded. 
The concentrated protein sample was diluted to ~0.1 mg/mL and appears on the far right. 
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2.6 Wildtype rcPEPCK crystallization and anion soaking 
WT PEPCK crystals were grown using both sitting-drop and hanging-drop vapour diffusion methods, at 
14 – 24% PEG 3350, 75 mM MnCl2, 100 mM HEPES pH 7.5, and 10 mg/mL protein. Crystals grew 
within a few days, with a rod-shaped morphology, and were harvested up to three days post crystallization 
as it was observed that the diffraction quality would begin to deteriorate with older crystals.  
WT PEPCK crystals were incubated in cryoprotectant containing a solution identical to the mother liquor, 
with the addition of 10% PEG 400 and potassium iodide ranging from 0 to 500 mM. Starting with 0 mM 
KI, the protein crystals were instantly dipped into 20 µL of cryoprotectant in a gradual, step-wise fashion 
to prevent cracking progressing through a range of: 0 mM, 10 mM, 25 mM, 50 mM, 100 mM, 250 mM, 
and 500 mM KI with the final KI concentration reflecting the final concentration of the salt the crystals 
were exposed to. Regardless of the final KI concentration, the crystals were incubated in the final KI 
solution for precisely 10 minutes. After incubation, the crystals were cryocooled by direct immersion in 
liquid nitrogen and mounted on the diffractometer. Our home source uses a rotating copper anode (CuKα 
= 1.54Å) to generate incident X-rays, and a Rigaku detector to read the resulting diffraction patterns.  
The detector was set roughly 160 mm away from the mounted crystal, and the crystal was centered in the 
X-ray beam and cryostream through careful adjustment of the goniometer. Each of the crystals were 
exposed to X-rays for 120 seconds, and diffraction patterns were collected at 1° intervals around the 
crystal, for a complete 360° dataset. Six different datasets were collected, one for each crystal soaked at 
each of the above listed KI concentrations. 
Each of the datasets were indexed as a primitive monoclinic Bravais lattice, integrated and scaled both 
anomalously and non-anomalously in a P21 spacegroup using HKL-2000.44 The resulting scalepack files 
were converted into .mtz files using CCP445, with only one PEPCK molecule in the ASU. The non-
anomalous datasets were used for structure solution as follows: molecular replacement was done via the 
MOLREP program using the WT rcPEPCK structure found on the PDB database (PDB ID: 2QEW).46 
Refinement was done using both CCP4 and Coot.47 Lastly, anomalous difference maps were generated by 
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scaling the diffraction data in an anomalous fashion and generating the resultant anomalous data file using 
CCP4. The anomalous data within this .mtz file was combined with amplitudes and phases from the 
refined structure, using the CAD program in CCP4 to merge the two files. Subsequently, this .mtz file 
was used as the input data for the FFT program to perform a Fourier transform, generating the anomalous 
difference map. The FFT program also has an option called ‘Peak Search’ that calculates anomalous peak 
heights above a certain intensity and lists them in a .pdb file. Using Coot to visualize the anomalous 
difference maps and the peak heights in the .pdb file, anomalous peak heights were assigned to PEPCK’s 
allosteric site for each dataset, corresponding to the allosteric anion occupancy for PEPCK crystals 
soaked at each iodide concentration. An allosteric binding isotherm was created by plotting the 
anomalous peak heights against the KI concentration. 
F284H and F284W rcPEPCK crystals were grown under the same crystallization conditions as the WT 
rcPEPCK crystals, with the additional step of seeding. A seed stock was created from a WT rcPEPCK 
crystal, and further seed stocks were created via serial dilutions of this initial solution. The seed stocks 
were created using a stabilizing solution of PEG 3350, PEG 400, HEPES and MnCl2 to mimic the 
reservoir solution. Mutant rcPEPCK crystals were grown at lower protein concentration ranging from 2 – 
6 mg/mL, and seeded with seed stocks diluted between 103 - 104. Mutant rcPEPCK crystals were 
subjected to the same iodide soaking protocol as the WT, albeit only a 250 mM potassium iodide dataset 
was collected on each of the mutant crystals. 
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2.7 Wildtype rcPEPCK kinetic activity and inhibition assays 
A standard enzyme activity assay was performed in both directions of the PEPCK-catalysed reaction. A 
Cary 100 UV-Vis dual-beam spectrophotometer was used to perform the assays. PEPCK activity was 
determined via a coupled assay using PK and LDH in the forward direction and MDH in the reverse 
direction (Figure 16). Reaction rates were measured spectrophotometrically at A340, corresponding to the 
depletion of NADH via coupled-enzyme kinetics. 
 
 
 
 
 
 
 
 
 
Figure 16: Coupled-enzyme reactions for the a) forward direction and b) reverse direction assays. The 
forward assay uses both PK and LDH coupling enzymes. The reverse assay uses MDH as a coupling 
enzyme. Underlined products represent substances that are used as substrates for the coupled reaction. The 
coupled-enzyme assay allows for the spectrophotometric detection of reaction rate via NADH depletion at 
340 nm. NADH and NAD+ are shown in purple. 
 
 
 
PEP + GDP + CO
2                     
OAA + GTP               PEPCK reaction: 
PEPCK 
OAA + NADH                Malate + NAD+ + H+  MDH reaction: 
MDH 
b) Reverse Direction of Catalysis 
OAA + GTP              PEP + GDP + CO
2
 PEPCK reaction: 
PEPCK 
PEP + ADP             Pyruvate + ATP  PK reaction: 
PK 
Pyruvate + NADH                Lactate + NAD+ + H+  LDH reaction: 
LDH 
a) Forward Direction of Catalysis 
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The assay mix in the forward direction contained 100 mM HEPES pH 7.5, 10 mM DTT, 4 mM MgCl2, 
100 µM MnCl2, 0.5 mM GTP, 1 mM ADP, 300 µM NADH, and 350 µM OAA, as well as 10 U of PK, 30 
U of LDH, and 2.5 µg of PEPCK at 0.5 mg/mL. The total assay volume was 1 mL. For the ‘reverse’ 
direction assay, concentrations of HEPES, DTT, NADH, MgCl2, MnCl2 and PEPCK remain the same, 
while 1 mM GDP, 4 mM PEP, 500 mM KHCO3 and 10 U of MDH are added instead. 
Assays were performed while varying each of the 4 possible substrates and keeping the rest of the 
substrates at a fixed and saturating concentration (at least 5 times the KM value). For the ‘forward’ 
direction, Michaelis-Menten curves were generated for both the OAA substrate and the GTP nucleotide, 
while curves for the ‘reverse’ direction were created for the PEP substrate and the GDP nucleotide. 
Anionic inhibition assays were also performed on WT PEPCK, by adding increasing amounts of 
potassium chloride. A series of five inhibition curves were plotted, one for each KCl concentration: 0 
mM, 5 mM, 15 mM, 25 mM, and 40 mM KCl in the ‘forward’ direction assay, and 0 mM, 10 mM, 25 
mM, 40 mM, and 100 mM KCl in the ‘reverse’ direction assay. The same anionic inhibition assay was 
repeated on the wildtype in the ‘reverse’ direction using iodide for comparison of the two anionic 
inhibitors. SigmaPlot’s Enzyme Kinetics module was used to generate the Michaelis-Menten curves, as 
well as calculate kinetic parameters including Vmax, KM and KI.  
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2.8 Mutant rcPEPCK kinetic activity and inhibition assays 
F284H and F284W rcPEPCK were characterized to determine new kinetic parameters for the nucleotides 
in both reaction directions as due to the proximity of the mutation to the nucleotide binding site it was 
possible that the KM value may have been increased in these enzyme variants. A standard activity assay as 
described above for the WT enzyme was performed in both the forward and reverse direction of catalysis, 
varying nucleotide concentration while keeping the other substrates constant (with the exception of 
MgCl2, which was kept at a 4:1 ratio with the varied nucleotide to form the metal-nucleotide substrate 
complex). Once the ideal concentration of GTP or GDP nucleotide was determined for maximum enzyme 
activity, inhibition assays were performed as described above for WT rcPEPCK. The chloride inhibition 
was determined for the F284H and F284W mutant isoforms up to a maximum concentration of 200 mM 
KCl. 
2.9 Kinetic re-plots for analysis of anionic inhibition data 
For the anionic inhibition studies, the kinetic data were fit nonlinearly to the standard Michaelis-Menten 
equation using SigmaPlot to determine KM and Vmax values corresponding to each inhibitor concentration 
(equation 1).1 The resulting KMapp values were re-plotted against the inhibitor concentration to calculate 
the KI value for chloride from a linear fit to equation 2.39 Non-specific effects of high salt concentration 
were determined using a similar approach by plotting Vmax against inhibitor concentration (equation 3). 
Equation 1:     𝑣 =
𝑉𝑚𝑎𝑥×[𝑆]
𝐾𝑀+[𝑆]
 
Equation 2:    
𝐾𝑀𝑎𝑝𝑝
𝑉𝑚𝑎𝑥 𝑎𝑝𝑝
=
𝐾𝑀
𝑉𝑚𝑎𝑥×𝐾𝐼
× [𝐼] + 
𝐾𝑀
𝑉𝑚𝑎𝑥
 
Equation 3:                 
1
𝑉max 𝑎𝑝𝑝
=
1
𝑉𝑚𝑎𝑥×𝐾𝐼
× [𝐼] +
1
𝑉𝑚𝑎𝑥
 
In equations 1-3, v is the initial velocity, Vmax is the maximal velocity, [S] is the concentration of 
substrate, KM is the Michaelis constant, [I] is the inhibitor concentration, and KI is the inhibition constant. 
For the data analysis Vmax is represented as the maximal specific activity of PEPCK.  
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Chapter 3: Results 
3.1 WT rcPEPCK Enzyme Kinetics 
WT rcPEPCK enzyme activity was measured both in the OAA → PEP direction and the PEP → OAA 
direction (Appendix B). Activity in the forward direction, as measured by kcat, was found to be 1.5-fold 
greater than that in the reverse direction. The same assay was performed by varying GTP/GDP, and a 
similar trend was observed (Table 5). 
Table 5: Kinetic characterization of WT rcPEPCK at 25°C. 
a) OAA + GTP → PEP + GDP + CO2 
 KM (µM)  kcat/KM (M-1 s-1) 
enzyme OAA GTP kcat (s-1) OAA GTP 
WT rcPEPCK 39.6 ± 4.8 54.6 ± 6.0 22.3 ± 0.7 5.6x105 4.1x105 
b) PEP + GDP + CO2 → OAA + GTP 
 KM (µM)  kcat/KM (M-1 s-1) 
enzyme PEP GDP kcat (s-1) PEP GDP 
WT rcPEPCK 206.3 ± 17.2 85.9 ± 9.3 15.0 ± 0.3 7.3x104 1.8x105 
All kinetic experiments were performed at 25°C. PEPCK activity was determined in the a) forward direction and b) 
reverse directions of catalysis via a coupled-enzyme assay. 
 
The KM for the PEP substrate is greater than that of the OAA substrate by 5-fold. This translates to an 
order of magnitude between the catalytic efficiency (kcat/KM) in the forward and reverse directions of 
catalysis. Although not as large a difference, the affinity for the nucleotide in the forward compared to 
reverse directions follows the same trend: the KM for GDP nucleotide is greater than that of GTP by about 
1.5-fold.   
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3.2 WT rcPEPCK Inhibition Kinetics 
Inhibition assays were performed on WT rcPEPCK as detailed in Section 2.7. A KI for chloride was 
determined for WT rcPEPCK in both the forward and reverse directions of catalysis (Table 6). 
 
Table 6: Chloride inhibition constants for wildtype rcPEPCK calculated from the kinetic re-plots 
(Appendix H) 
a) OAA + GTP → PEP + GDP + CO2  
Variable Substrate 
KM/Vmax 
KI (mM) 
1/Vmax 
KI (mM) 
OAA 120.5 ± 0.43 757.1 ± 0.43 
b) PEP + GDP + CO2 → OAA + GTP  
Variable Substrate 
KM/Vmax 
KI (mM) 
1/Vmax 
KI (mM) 
PEP 14.1 ± 3.7 290.3 ± 0.01 
All kinetic experiments were performed at 25°C. Chloride inhibition was determined in the a) forward direction and 
b) reverse directions of catalysis via a coupled-enzyme assay. Error associated with the KI’s were obtained from a 
linear regression of the kinetic data using the LINEST function in Excel. 
 
An inhibition assay performed in the reverse direction demonstrated a strong inhibitory effect of chloride 
ions on the wildtype enzyme (Table 6b), yielding a competitive KI of 14.1 ± 3.7 mM. Conversely, 
exposing WT rcPEPCK to increasing concentrations of chloride in the forward direction of catalysis gives 
a competitive KI of 120.5 ± 0.43 mM (Table 6a). Chloride inhibition in the reverse direction is 9-fold 
greater than that of the forward or physiological direction of gluconeogenesis. 1/V effects of the inhibitor 
on the enzyme were also observed, but these had a lesser effect on inhibition than K/V. The K/V effect 
was 6-fold and 20-fold greater than the 1/V effect in the forward and reverse directions respectively. 
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3.3 WT rcPEPCK Crystallization 
WT rcPEPCK crystals were grown using both the sitting and hanging-drop vapour diffusion methods. 
Crystal conditions were optimized to obtain the largest and most robust crystals (Figure 17) to achieve the 
best diffraction quality possible at our home source. The crystal quality and size were found to be highly 
dependent on the concentration of the PEG 3350 precipitant with an optimal concentration range of 18-
20% (Figure 17B). 
 
Figure 17: Optimizing crystallization conditions for WT rcPEPCK. Crystal morphology 
when grown at 14-16% PEG 3350 (A), 18-20% PEG 3350 (B), 22-24% PEG 3350 (C) 
and 24-26% PEG 3350 (D). All crystals were observed using an Olympus SZX16 
microscope. 
 
 
A: 14-16%  
PEG 3350 
B: 18-20%  
PEG 3350 
 
C: 22-24%  
PEG 3350 
 
D: 24-26%  
PEG 3350 
100 µm 100 µm 
100 µm 100 µm 
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Crystals with optimal morphology were harvested and incubated in cryoprotectant containing iodide as 
outlined in Section 2.6 (Figure 18). Soaking into increasing concentrations of iodide was performed in a 
step-wise manner to avoid deterioration of crystal structure (See Section 2.6 for anion soaking). 
 
   
 
 
 
 
 
 
 
 
Figure 18: Iodide soaking of WT rcPEPCK crystals. Cryoprotectants (left) contained a solution 
identical to the reservoir solution of the crystals, with the addition of PEG 400 and potassium iodide (0-
500 mM). Crystals were incubated with cryoprotectant (right) before flash cooling in liquid N2. 
 
 
3.4 Structure solution of WT rcPEPCK and determination of anion binding via the 
anomalous diffraction of iodide 
Analysis of an initial WT rcPEPCK crystal soaked in 500 mM iodide revealed the presence of iodide 
bound to the active site. Comparing the location of the anomalous signal to a structure of WT rcPEPCK 
with substrate bound at the active site (PDB ID: 4GNP) demonstrates that iodide binds competitively to 
PEPCK at the OAA/PEP binding site (Figure 19).34                                                                                                                                
    
Potassium Iodide Cryoprotectants 
0                                                          500 mM 
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Figure 19: Superimposition of anomalous signal onto WT rcPEPCK structure with PEP substrate 
(PDB ID: 4GNP). Two catalytically important mobile loops in the active site, the R-loop (residues 
85-92) and the P-loop (residues 284-292) are coloured yellow and pink respectively. PEP is rendered 
as a stick model coloured by atom type, and the M1 manganese ion is shown as a grey sphere. 
Anomalous signal is shown as an orange electron density. All graphics were generated using 
CCP4MG.37  
 
Further soaking of multiple PEPCK crystals over a range from 10 mM to 500 mM potassium iodide 
showed anomalous signal at another site located behind the P-loop (Figure 20). In contrast with the active 
site signals, this anomalous signal was unique because it appeared to titrate over the range of iodide 
concentrations used (Figure 21). The range of iodide used for crystal soaking was determined from the 
observed KI for the kinetic inhibition phenomenon observed above (10-500 mM). These new data led us 
to hypothesize that anion binding to this putative allosteric site was the source of the observed inhibition 
rather than a competitive mechanism of inhibition from anion binding to the active site. See Appendix I 
for a complete list of all iodides bound to PEPCK. 
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Figure 20: Allosteric site and active site binding sites of WT rcPEPCK. Two catalytically important 
mobile loops in the active site, the R-loop (residues 85-92) and the P-loop (residues 284-292) are 
coloured yellow and pink respectively. The M1 manganese ion is shown as a grey sphere, and the 
anomalous signals are represented as orange electron density. All graphics were generated using 
CCP4MG.37 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Titration of anomalous signal over the range of iodide soaking. Anomalous signal at the active 
site remains constant from low (A) to high (B) concentration of iodide used. Anomalous signal at the 
putative allosteric site titrates from low (C) to high (D) concentrations of iodide. Due to weak electron 
density, the P-loop was not modelled in the final structure. Anomalous difference map is represented as 
orange electron density.  
 
 
A 
C 
B 
D 
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Through the quantification of the anomalous signal found at the allosteric site, we can begin to understand 
the role anions play in the regulation of PEPCK activity. Plotting the anomalous peak height of iodide 
against the concentration of iodide used in each crystal soak, a type of binding isotherm can be generated 
for the allosteric site (Table 7, Figure 22). 
Table 7: Anomalous peak height at the allosteric site corresponding to each potassium iodide soak 
[Iodide] (mM) Mn2+ Anom. Peak 
Height (e-/Å3) 
Allosteric Anom. Peak 
Height (e-/Å3) 
*Norm. Anom. Peak 
Height (e-/Å3) 
10 16.23 6.26 0.386 
25 17.28 10.41 0.602 
50 15.8 11.54 0.730 
100 11.56 10.72 0.927 
250 11.26 12.02 1.067 
500 13.7 13.68 0.999 
*Peak heights were normalized by dividing by the anomalous peak height of their corresponding Mn cations. 
 
 
  
 
 
 
 
 
 
 
 
Figure 22: WT rcPEPCK allosteric binding isotherm for iodide. Normalized 
anomalous peak height values were calculated by dividing the allosteric anomalous 
peak height by that of the Mn (M1) cation, and then fit hyperbolically (See Section 
2.9, Equation 1) against the range of iodide concentration used for anion soaking. 
This plot was generated using SigmaPlot 11. 
The KD for iodide bound to the allosteric site was determined to be 20.0 ± 3.8 mM. This value is on the 
same order of magnitude as the chloride inhibition constant for WT rcPEPCK in the reverse direction of 
catalysis (KI of 14.1 ± 3.7 mM), despite using iodide as the inhibitor. 
K
D
 = 19.9 ± 1.9 mM 
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3.5 Structural analysis of the allosteric site 
Looking closer at the putative allosteric site, we observe that it is in close proximity to the P loop, and as 
such many of the amino acids contributing to iodide binding also play in role in nucleotide binding 
(Figure 23). Consistent with the mM binding constant observed for chloride, iodide is found to be 
coordinated in the allosteric ‘pocket’ by numerous weak interactions that are all greater than 4Å away.  
 
 
Figure 23: Putative allosteric site of WT rcPEPCK. The P-loop is coloured pink 
and iodide ion is shown as a large grey sphere. Residue side chains are labelled 
and coloured by atom type, and the distances between them and the iodide ion are 
listed in Angstroms. All graphics were generated using CCP4MG.37 
 
It is important to note that when anions are not present in high concentration, the pocket occupies a closed 
conformation, but upon anion binding, the P-loop undergoes a conformational change that is unfavourable 
for catalytic function (Figures 24 & 25). In this anion-bound state, the P-loop is observed to be in a 
disordered and therefore difficult to model conformation, due to the resultant weak electron density from 
the disordered loop element.  
 
 
PHE284 
PRO285 
PHE517 
SER462 
ARG436 
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Figure 24: Conformational change of the P loop upon iodide binding. The R-loop is coloured yellow, and the unbound 
and anion-bound conformations of the P-loop are coloured pink and orange respectively. The M1 manganese cation 
is shown as a small grey sphere in the centre of the active site. Iodide ions are represented as larger grey spheres. All 
graphics were generated using CCP4MG.37  
 
 
Figure 25: Superimposition of iodide-bound and unbound structures of WT rcPEPCK. The P-loop undergoes a 
conformational change upon binding iodide to the allosteric pocket. The sulfhydryl group of Cys288 occupies the 
allosteric site in the absence of iodide. The unbound structure is coloured green, while the iodide-bound structure is 
coloured yellow by default. Electron density of the iodide-bound structure is shown in blue, and the corresponding 
anomalous difference map for the 250 mM KI structure is shown in orange. The residue Cys288 is labelled on both 
structures. All graphics were rendered in Coot.47 
Cys288 
Cys288 
Phe284 
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Table 8: Crystallographic Data and Model Statistics 
 0mM Iodide 10mM Iodide 25mM Iodide 50mM Iodide 100mM Iodide 250mM Iodide 500mM Iodide 
Wavelength (Å) 1.54 1.54 1.54 1.54 1.54 1.54 1.54 
Space Group P1 21 1 P1 21 1 P1 21 1 P1 21 1 P1 21 1 P1 21 1 P1 21 1 
Unit Cell Dimensions a = 45.3 
b = 118.9 
c = 61.2 
ɑ = γ = 90.0° 
β = 108.5° 
a = 45.4 
b = 118.4 
c = 61.3 
ɑ = γ = 90.0° 
β = 108.7° 
a = 45.4 
b = 118.6 
c = 61.2 
ɑ = γ = 90.0° 
β = 108.5° 
a = 45.5 
b = 118.5 
c = 61.4 
ɑ = γ = 90.0° 
β = 109.2° 
a = 45.1 
b = 118.9 
c = 60.8 
ɑ = γ = 90.0° 
β = 110.9° 
a = 45.5 
b = 118.6 
c = 61.1 
ɑ = γ = 90.0° 
β = 110.8° 
a = 45.5 
b = 118.8 
c = 61.1 
ɑ = γ = 90.0° 
β = 111.0° 
Resolution Limits (Å) 41.58 – 1.95 41.56 – 2.00 41.52 – 2.10 34.83 – 2.10 42.19 – 2.45 42.02 – 2.27 34.58 – 2.25 
No. of unique reflections 37512 36219 32344 32543 20753 26351 27035 
Completeness (%) 88.5 (31.9) 92.0 (47.5) 95.4 (61.6) 95.5 (66.5) 99.2 (91.6) 99.4 (93.8) 99.0 (87.6) 
Redundancy 6.8 (3.4) 6.8 (3.3) 7.1 (4.7) 6.9 (3.5) 6.6 (5.0) 6.8 (4.8) 6.3 (4.1) 
I/sigma 23.4 (2.1) 19.3 (1.6) 20.4 (1.9) 16.1 (1.7) 19.1 (2.0) 15.8 (1.7) 11.1 (1.4) 
Rmerge 0.07 (0.39) 0.07 (0.43) 0.07 (0.49) 0.08 (0.48) 0.07 (0.62) 0.11 (0.57) 0.15 (0.66) 
No. of ASU molecules 1 1 1 1 1 1 1 
Rfree 0.24 (0.38) 0.26 (0.39) 0.27 (0.38) 0.25 (0.41) 0.27 (0.47) 0.25 (0.44) 0.27 (0.35) 
Rwork 0.19 (0.36) 0.21 (0.37) 0.22 (0.35) 0.21 (0.33) 0.21 (0.36) 0.20 (0.33) 0.21 (0.34) 
Average B factor (Å2) 
protein 
Mn, Na 
waters 
I 
  
41.9 
43.9 
40.0 
- 
 
52.5 
46.3 
47.1 
76.7 
 
51.2 
43.3 
43.6 
77.4 
 
50.6 
45.1 
43.1 
69.2 
 
58.9 
61.1 
50.1 
86.1 
 
52.5 
48.3 
49.2 
81.0 
 
51.9 
48.2 
49.1 
71.9 
Estimated coordinate error based on 
maximum likelihood (Å) 
0.135 0.176 0.198 0.176 0.269 0.200 0.221 
Bond length rmsd (Å) 0.006 0.005 0.006 0.005 0.002 0.003 0.003 
Bond angle rmsd (deg) 1.364 1.356 1.389 1.360 1.232 1.264 1.241 
Molprobity statistics (score, percentile, 
no. of Ramachandran outliers) 
1.17, 100th, 2 1.56, 95th, 2 1.72, 93th, 1 1.56, 97th, 1 1.61, 99th, 1 1.59, 98th, 5 1.52, 99th, 5 
*Values in parentheses represent those in the highest resolution shell. 
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3.6 Design of Allosteric Mutants 
To investigate allosteric regulation, PEPCK mutants were created in order to perturb anion binding. F284 
was chosen for mutagenesis as one of the only residues of the allosteric pocket that does not have a direct 
role in substrate binding, or an integral part of a dynamic loop (Figure 23).  
Two different PEPCK mutants were created, both with variations of residue 284: F284H and F284W 
(Figure 27). In order to retain proper protein folding, the mutations introduced needed to have the same 
properties as the wildtype, so histidine and tryptophan were chosen for their non-polar aromatic side 
chains. Tryptophan is a much larger aromatic residue than histidine or phenylalanine, so it was 
hypothesized to have the greatest perturbation of the allosteric site. 
The same kinetic and structural experiments were performed on the allosteric mutants for comparison to 
the wildtype enzyme to investigate allosteric regulation of PEPCK. 
 
 
 
Figure 26: F284 of WT rcPEPCK. Phenylalanine was chosen for 
mutagenesis. The phenylalanine side chain is coloured by atom type, and 
iodide is represented as a large grey sphere. 
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Figure 27: Superimposition of PEPCK mutants onto the wildtype enzyme. The WT phenylalanine residue 
is coloured light blue, while the histidine (left) and tryptophan (right) residues are coloured by atom type. 
Iodide is represented as a large grey sphere. All graphics were generated using CCP4MG.37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F284H mutant F284W mutant 
 38 
 
3.7 Mutant PCR Mutagenesis, Transformation and Protein Expression 
Mutant strains of rcPEPCK were created using specially designed primers to introduce the mutation via 
PCR mutagenesis (see Section 2.4), using the P-SUMOstar expression vector containing the WT 
rcPEPCK DNA sequence as the template. PCR products were run on an agarose gel for confirmation 
(Figure 28), transformed into the XL1 E. coli cloning cell line for plasmid replication (Figure 29), and 
then into the BL21 E. coli expression cell line for PEPCK expression (Figure 30). After sequencing to 
ensure successful mutagenesis of the allosteric site, the F284H and F284W mutants were expressed and 
purified using the same protocol as described in Section 2.5. 
 
 
 
Figure 28: Agarose gel results of PCR mutagenesis for F284H and F284W mutants. 
Each mutant PEPCK pSUMO star vector is loaded onto the gel in triplicate, 
corresponding to the annealing temperature during PCR. The mutant rcPEPCK 
plasmid is ~8.4 kb in size. 
 
 
 
 
 
 
F284H F284W 
55°C 55°C 60°C 60°C 65°C 65°C 
1 kb 
ladder 
1 000 
750 
500 
250 
10 000 
6 000 
3 000 
2 500 
2 000 
1 500 
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Figure 29: Transformation of the F284H and F284W PEPCK plasmids into XL1 E. 
coli cloning cell line. PCR products were transformed into the XL1 cloning cell line 
via heat shock. The streak-plate method was used along with kanamycin selection 
to find colonies that had successfully taken up the plasmid.  
 
 
 
 
    
Figure 30: Transformation of F284H (left) and F284W (right) rcPEPCK plasmids 
into BL21 E. coli expression cell line. The streak-plate method was again used along 
with kanamycin selection, resulting in colonies with a round, opaque, beige coloured 
morphology.  
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3.8 Mutant rcPEPCK Protein Purification and Crystallization 
Mutant rcPEPCK was purified using the same protocol as the WT rcPEPCK enzyme. Initially the WT 
rcPEPCK crystallization conditions were used, however, both the F284H and F284W mutant isozymes of 
rcPEPCK proved difficult to crystallize. These mutant crystals were smaller, appeared cracked or 
fractured (Figure 31), and were more two-dimensional instead of the 3-D rod morphology of the wildtype 
enzyme. Of the two mutant isoforms, the tryptophan mutant, F284W was the most difficult to crystallize. 
    
Figure 31: Mutant crystals harvested and soaked in cryoprotectant. F284H and F284W 
rcPEPCK crystals appear cracked and fractured in comparison to the wildtype crystals. 
Crystals were observed using an Olympus SZX16 microscope. 
 
 
In attempt to grow crystals with better morphology and diffraction quality, crystal seeding was performed. 
Mutant rcPEPCK was grown at lower protein concentrations ranging from 2 to 6 mg/mL instead of the 
standard 10 mg/mL, and was seeded 24 hrs after equilibration of the protein drop at 21°C. Crystal seeding 
encouraged nucleation and mutant rcPEPCK crystals formed. 
 
100 µm 100 µm 
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Figure 32: F284H (left) and F284W (right) rcPEPCK crystals after seeding. F284H 
crystals have a two-dimensional sheet-like morphology (left) and F284W crystals have 
an irregular rod-shaped morphology (right). 
 
Mutant crystals were harvested and soaked in cryoprotectant containing 250 mM potassium iodide using 
the same protocol as described in Section 2.6. These crystals were diffracted at our home source (Table 
9), and the anomalous signal was analyzed to determine iodide binding at the allosteric site.
100 µm 100 µm 
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3.9 Mutant rcPEPCK X-ray Diffraction 
 
Table 9: Crystallographic Data and Model Statistics for Mutant rcPEPCK 
 F284H 250mM KI F284W 250mM KI 
Wavelength (Å) 1.54 1.54 
Space Group P1 21 1 P1 21 1 
Unit Cell Dimensions a = 45.3 
b = 118.7 
c = 60.9 
ɑ = γ = 90.0° 
β = 111.5° 
a = 45.1 
b = 118.2 
c = 60.7 
ɑ = γ = 90.0° 
β = 111.9° 
Resolution Limits (Å) 59.34 – 2.09 28.90 – 2.34 
No. of unique reflections 33311 22795 
Completeness (%) 99.1 (93.1) 96.6 (89.7) 
Redundancy 7.1 (6.9) 7.5 (6.7) 
I/sigma 13.3 (2.4) 13.9 (1.8) 
Rmerge 0.10 (0.76) 0.09 (0.98) 
No. of ASU molecules 1 1 
Rfree 0.26 (0.45) 0.28 (0.38) 
Rwork 0.22 (0.35) 0.22 (0.34) 
Average B factor (Å2) 
protein 
water 
Mn 
I 
 
50.8 
48.7 
47.1 
71.6 
 
52.0 
46.6 
52.3 
67.1 
Estimated coordinate error based 
on maximum likelihood (Å) 
0.178 0.256 
Bond length rmsd (Å) 0.003 0.002 
Bond angle rmsd (deg) 1.224 1.234 
Molprobity statistics (score, 
percentile, no. of Ramachandran 
outliers) 
1.65, 95th, 2 1.89, 94th, 2 
*Values in parentheses represent those in the highest resolution shell. 
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Table 10: Anomalous peak height at the allosteric site with mutant rcPEPCK data added 
[Iodide] (mM) Mn2+ Anom. Peak 
Height (e-/Å3) 
Allosteric Anom. 
Peak Height (e-/Å3) 
*Norm. Anom. Peak 
Height (e-/Å3) 
WT rcPEPCK    
10 16.23 6.26 0.386 
25 17.28 10.41 0.602 
50 15.8 11.54 0.730 
100 11.56 10.72 0.927 
250 11.26 12.02 1.067 
500 13.7 13.68 0.999 
F284H rcPEPCK    
250 21.83 5.73 0.262 
F284W rcPEPCK    
250 10.91 0 0 
*Peak heights were normalized by dividing by the anomalous peak height of their corresponding Mn cations. 
 
The F284H mutant shows a decreased anomalous signal compared to that of the wildtype at the same 
iodide concentration. At 250 mM potassium iodide, the anomalous signal at the allosteric site is 
approximately 4-fold greater for the wildtype than the histidine mutant (Table 10). No anomalous signal 
was observed for the allosteric site of the F284W mutant. Both of the mutants showed anomalous signal 
corresponding to iodide binding at the active site, comparable to what was found in the WT rcPEPCK 
structure.  
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Figure 33: Anomalous signal at the allosteric site for WT and mutant rcPEPCK. Anomalous signal represented as 
orange electron density. Comparison of iodide binding to each of the allosteric mutants as well as the disordered 
conformation of the P-loop, most notable in the F284H and F284W mutants. 
 
 
 
 
 
 
 
 
 
F284H 
250 mM I- 
F284W 
250 mM I- 
WT 
250 mM I- 
WT 
0 mM I- 
 45 
 
3.10 Mutant rcPEPCK Kinetic Characterization 
Before inhibition assays could be performed on the F284H and F284W mutants, these new enzyme 
variants had to be characterized. It was hypothesized that due to the proximity of the allosteric site to the 
P-loop, it was likely that the KM for GTP/GDP would have changed from that of the wildtype. 
The KM for the GTP and GDP nucleotides were determined (Table 11), and these kinetic parameters were 
used for the inhibition assays such that at least 4 times the KM was added for each of the nucleotides. 
Mutation of residue 284 increased the KM for GTP by 12-fold for both the histidine and tryptophan 
mutants, while increasing the KM for GDP by 2.5-fold and 12-fold for histidine and tryptophan 
respectively. 
 
Table 11: Kinetic characterization of F284H and F284W rcPEPCK mutants 
a) OAA + GTP → PEP + GDP + CO2 
 KM (µM)  kcat/KM (M-1 s-1) 
enzyme OAA GTP kcat (s-1) OAA GTP 
WT 39.6 ± 4.8 54.6 ± 6.0 22.3 ± 0.7 5.6x105 4.1x105 
F284H 65.8 ± 10.6 645.7 ± 150 27.7 ± 1.3 4.2x105 4.5x104 
F284W 89.2 ± 12.6 661.7 ± 154 28.3 ± 1.3 3.2x105 4.4x104 
b) PEP + GDP + CO2 → OAA + GTP 
 KM (µM)  kcat/KM (M-1 s-1) 
enzyme PEP GDP kcat (s-1) PEP GDP 
WT 206.3 ± 17.2 85.9 ± 9.3 15.0 ± 0.3 7.3x104 1.8x105 
F284H 236.4 ± 25.1 219.9 ± 30.8 15.1 ± 0.4 6.4x104 8.0x104 
F284W 126.6 ± 15.4 986.5 ± 136 4.0 ± 0.09 3.1x104 5.2x103 
All kinetic experiments were performed at 25°C. PEPCK variants were characterized in a) the forward direction and 
b) the reverse direction of catalysis. 
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3.11 Mutant rcPEPCK Inhibition Kinetics 
 
Table 12: Expanded table of inhibition constants for wildtype and mutant rcPEPCK 
c) OAA + GTP → PEP + GDP + CO2 (Chloride) – using OAA as the variable substrate 
enzyme 
KM/Specific Activity 
KI (mM) 
1/Specific Activity 
KI (mM) 
WT 120.5 ± 0.43 757.1 ± 0.43 
F284H 171.8 ± 1.0 264.5 ± 0.01 
F284W 95.1 ± 0.35 97.3 ± 0.01 
d) PEP + GDP + CO2 → OAA + GTP (Chloride) – using PEP as the variable substrate 
enzyme 
KM/Specific Activity 
KI (mM) 
1/Specific Activity 
KI (mM) 
WT 14.1 ± 3.7 290.3 ± 0.01 
F284H 18.9 ± 2.7 412.0 ± 0.01 
F284W 30.7 ± 6.9  95.0 ± 0.19 
e) PEP + GDP + CO2 → OAA + GTP (Iodide) – using PEP as the variable substrate 
enzyme 
KM/Specific Activity 
KI (mM) 
1/Specific Activity 
KI (mM) 
WT 33.8 ± 100 8.42 ± 0.04 
f) Binding Isotherm for Allosteric Site 
 KD (mM) 
WT 20.0 ± 3.8 
 
Inhibition assays on the PEPCK mutants showed that mutating the allosteric site does not have a 
significant effect on inhibition in the physiological direction of gluconeogenesis. However, introducing 
these mutations at position 284 does have an interesting effect on inhibition in the reverse direction. The 
F284H mutant does alleviate inhibition in the reverse direction, but only very minimally, especially when 
compared to the reduction of iodide binding revealed from the structural data. The F284W mutant had the 
weakest inhibition, with roughly half the inhibitory strength compared to the WT, but the kinetic data 
does not correlate with the complete lack of iodide binding seen in the structural data. 
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There is a notable discrepancy between the kinetic and structural data due to the use of two different 
anions: chloride for the kinetic inhibition assays, and iodide for the structural approach. To attempt to tie 
the data together, the kinetic inhibition assays were repeated on the WT rcPEPCK enzyme, this time using 
iodide. The inhibition constant was determined for iodide in the reverse direction, and was compared to 
its chloride counterpart. It was discovered that chloride is the stronger competitive inhibitor (KI of 14.1 
mM)(Figure H1) and despite being the smaller of the two anions, chloride is approximately twice as 
effective at inhibiting PEPCK activity compared to iodide (KI of 33.8 mM)(Figure H7). 
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Chapter 4 Discussion  
4.1 Kinetic characterization and anionic inhibition of WT rcPEPCK 
Kinetic assays performed on the WT enzyme supported what numerous other studies had identified: 
PEPCK activity in the PEP → OAA direction, referred to as the reverse direction of catalysis, is 
significantly reduced compared to the OAA → PEP direction, which is considered the physiological 
direction of gluconeogenesis. This is demonstrated by the catalytic efficiency as seen in Table 5; there is 
an order of magnitude difference between the kcat/KM for OAA in the forward direction and PEP in the 
reverse direction. PEPCK activity in the forward direction is easily demonstrated in vivo, despite the 
difficulty in performing the forward direction assay in vitro. There are several intricacies involved with 
the assay, including obtaining pure substrates for enzymatic assay, but most notably being the 
spontaneous decarboxylation of OAA by the high concentration of metal cations required for PEPCK 
function.48 This background rate is subtracted from the total reaction rate to obtain the true reaction rate 
for PEPCK.  
The kinetic data also shows the difference in affinity PEPCK has for the OAA/PEP substrates. The KM for 
OAA is lower than that of PEP by an order of magnitude, again demonstrating a preference for the 
forward direction over the reverse direction of catalysis. However, these values for the substrates likely 
only represent the apparent KM, calculated based on the kinetic data. Despite the fact that the PEPCK-
catalyzed reaction is thermodynamically reversible, PEPCK primarily catalyzes the conversion of OAA to 
PEP in higher eukaryotes.3 The kinetic data shows that PEPCK does not act in a unidirectional manner in 
vitro, and will catalyze the reaction in either direction given the appropriate substrates, however, it is 
apparent that enzyme activity in the reverse direction of catalysis is inhibited by some mechanism. Our 
initial hypothesis concluded that there was some significant difference between the PEPCK assay in vitro 
and the intracellular environment in vivo. The kinetic assay has been optimized by only including the 
minimum substrates and buffers required for PEPCK activity. This includes the mandatory metal cations 
that act as PEPCK cofactors, Mg2+ and Mn2+.49,50 However, these cations are added as chloride salts, 
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which consequently has the disadvantage of adding 4 mM chloride to the assay mixture. It was 
hypothesized that this abundance of chloride in the kinetic assay leads to the inhibition of the WT 
rcPEPCK enzyme in the PEP → OAA direction in vitro, and would likely have an even stronger 
inhibitory effect on PEPCK in vivo, considering the high concentration of chloride as well as many other 
anions in a biological cell.26,27 
To test the hypothesis of anionic inhibition, chloride was chosen as the anionic inhibitor due its 
abundance in biological systems. As one of the most ubiquitous anions of the halide family, chloride 
would be the most physiologically relevant anion to play a role in the regulation of PEPCK activity. 
Additional chloride was added to the standard PEPCK assay, and the competitive inhibition constant, KI, 
was determined for chloride in both the forward and reverse directions of catalysis (Table 6). The KI in 
the PEP → OAA was calculated to be approximately 14.1 mM of chloride, compared to the significantly 
weaker inhibition in the OAA → PEP direction, calculated to be approximately 120.5 mM. This is an 
entire order of magnitude difference in the inhibition constants, similar to the difference in the 
aforementioned catalytic efficiency between the forward and reverse directions of catalysis. The KI for 
chloride in the forward or physiological direction of gluconeogenesis is quite high, and as such chloride 
inhibition does not significantly affect PEPCK activity in the OAA → PEP direction, whether it is in vitro 
or in vivo. Conversely, the KI for chloride in the reverse direction is comparatively low, resulting in a 
stronger inhibition on PEPCK activity. Considering the average biological cell has upwards of 100 mM of 
chloride, it becomes apparent how PEPCK activity is regulated for the gluconeogenic pathway.26,27 It is 
this difference in anionic inhibition between the forward and reverse directions of catalysis that likely 
allows for kinetic regulation, despite the fact that the PEPCK-catalyzed reaction is thermodynamically 
reversible. 
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4.2 Structural determination of anion binding to WT rcPEPCK via anomalous diffraction 
X-ray crystallography, combined with the anomalous diffraction of iodide, was used to examine anion 
binding to PEPCK. Iodide was used as the anionic inhibitor as a proxy for chloride, due to its unique 
anomalous properties. WT rcPEPCK crystals were soaked in 500 mM potassium iodide and diffracted at 
our home source (CuКα = 1.54Å), then the resulting diffraction patterns were analyzed to generate both 
the WT structure and a corresponding anomalous difference map. Iodide was easily located at the active 
site, tightly bound at the OAA/PEP site as expected of a competitive inhibitor (Figure 19).  
Further crystal soaking experiments revealed the presence of an allosteric site, located directly behind the 
P-loop, where the anomalous signal appeared to titrate with increasing iodide concentration (Figure 20-
21). This contrasts the anomalous signal at the active site, which remains relatively constant over the 
range of concentration used for the iodide soaks, and only begins to decrease at the lowest iodide 
concentration used. The putative allosteric site does not appear to have the tetrahedral geometry of known 
anion-binding sites, so further analysis is needed. 
The iodide bound to the allosteric site is unique due in its observed titration when compared to all other 
iodide anions found in the WT rcPEPCK structure (listed in Appendix I). There is a total of eighteen 
iodide anions found in the 500 mM KI wildtype structure, most of which are bound to the surface of the 
enzyme. The two iodide anions present in the active site are non-titratable, demonstrating a behaviour 
similar of that to the surface-bound iodides (Appendix I). Each of the iodides in the active site has an 
occupancy of approximately 0.5, indicating that there is only one iodide truly bound to the active site, and 
that the iodide is likely to be bound in either of these two positions located in the OAA/PEP site. This is 
an artifact of macromolecular X-ray diffraction, in that a dataset is the average of all of the molecules that 
comprise the crystalline lattice. It is interesting to note that one of these anomalous signals in the active 
site disappears in the 10 mM KI structure, indicating that at lower concentrations of iodide (likely on the 
micromolar scale) this anomalous signal could start to titrate. Overall, only the iodide bound to the 
allosteric site was observed to titrate over the range of iodide concentration used in both the kinetic assays 
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as well as the aforementioned crystal soaking experiments. Using the anomalous scattering of iodide to 
analyze occupancies of bound anions is a fairly recent method of using iodide soaking, that which was 
previously only used to obtain phase information.51 
Generation of a binding isotherm using the anomalous peak height plotted against iodide concentration 
allowed us to calculate an approximate binding constant for the allosteric site (Figure 22). The KD for 
iodide at the allosteric site was determined to be 20.0 mM. We can compare this binding constant to the 
inhibition constant from the kinetic assays: the KD is remarkably similar to the KI for chloride in the 
reverse direction of catalysis. This addresses several questions about the kinetic data, such as if the 
competitive inhibition seen from the PEPCK assays is a combination of anions binding to both the 
allosteric and active sites. The structural data provides evidence that the regulation of PEPCK in a 
biological system is due primarily to binding at the allosteric site, and not the active site, as one would 
initially expect of a competitive inhibitor. Without anions present in the crystallization conditions, the 
pocket is closed and the P-loop can undergo the conformational changes necessary to bind the nucleotide 
substrate. Binding to the allosteric site causes the P-loop to become disordered (Figure 24), directly 
affecting nucleotide binding. Disorder of the P-loop correlates to a change in apparent KM for the 
nucleotide as well as the PEP substrate (Michaelis-Menten curves in Appendix C), due to the decreased 
binding of GDP and the rate of phosphoryl transfer between nucleotide and PEP substrate. 
Interestingly, in the unbound state of WT rcPEPCK, the sulfhydryl group of C288 appears to occupy the 
allosteric pocket in nearly the same position as the iodide in the anion-bound state (Figure 25). This hyper-
reactive cysteine is essential for catalysis and therefore PEPCK activity is known to be inhibited through 
reduction of the sulfhydryl group or substitution of the cysteine for another amino acid.52 Perturbing the 
conformation of the P-loop and therefore the positioning of C288 likely contributes to the decrease in 
PEPCK activity seen in the chloride inhibition assays. 
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4.3 Structural solution of rcPEPCK mutants and determination of allosteric binding via 
anomalous diffraction 
To determine if this is indeed an allosteric pocket despite not resembling known anion-binding sites, 
PEPCK mutants were created to examine the effect on anion binding and enzyme activity. Iodide is 
bound to the pocket by weak interactions with the peptide backbone, and aromatic residues greater than 
4Å away (Figure 23). Due to the proximity to the active site, many of the amino acids that comprise the 
pocket are integral to enzyme function. F517 and R346 are part of the P-loop and involved in nucleotide 
binding respectively, while S462 is an integral part of the Ω-loop lid.11,34 F284 was chosen for 
mutagenesis, because it has no previously known role for enzyme function (Figure 26). In order to 
conserve protein folding and enzyme function, phenylalanine was mutated to two other aromatic residues, 
histidine and tryptophan (Figure 27). Due to the difference in size between the histidine and tryptophan 
residues, it was hypothesized that the F284W mutant would have the more significant effect on anion 
binding compared to the more conservative F284H mutant. 
The F284H and F284W rcPEPCK mutant crystals were grown using the same protocol as the wildtype. 
Initial screening of these mutant crystals yielded poor diffraction patterns, therefore seeding was used to 
improve nucleation and overall crystal quality. Crystals were soaked in 250 mM potassium iodide and 
diffracted at our home source. One immediate difference between the mutants and the WT was the 
conformation of the P-loop. Upon binding to the allosteric site, the P-loop changes to a slightly more 
disordered conformation in the wildtype, however, binding to the allosteric mutants F284H and F284W 
leads to a much higher state of disorder. As such, the P-loop is not modelled in the mutant PEPCK 
structures (Figure 33). Generation of anomalous difference maps yielded nine additional iodide anions 
that were not present in the wildtype structures, though these iodides were surface-binding and expected 
to be non-titratable (See Appendix I).  
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Examining the allosteric site of the F284H mutant shows a decreased anomalous peak height 
approximately one fourth of the anomalous signal found at the wildtype’s allosteric site when soaked at 
the same iodide concentration (Table 12). This supports the hypothesis that the phenylalanine at position 
284 has a role in anionic binding, even if only through weak interactions. Mutating phenylalanine to 
histidine, although the mutated residue retains aromaticity and similar size, decreases the electrostatic 
interactions with iodide in some way. It is possible that F284 binds iodide to the pocket through anion-π 
or anion-quadrupole interactions, which are known to occur between an anionic species and the 
electropositive edge of an aromatic ring.53–55 Aromatic ring systems can have a quadrupole moment as a 
result of their π electrons interacting with nearby positively charged amino acids, leaving behind an 
electron-deficient aromatic ring.56 Another of the allosteric residues, not chosen for mutagenesis, F517 
also appears to be positioned edgewise for anion-π interaction with the bound iodide (Figure 23). Further 
research is needed to determine whether an anion-π interaction is plausible between the aromatic residues 
of the allosteric pocket and anionic ligands. Both the benzene ring of phenylalanine and the neutral 
imidazole ring of histidine act are able to act as aromatic systems. Along with their similar size, this 
explains how the F284H mutant retains some level of anionic binding, as demonstrated in the anomalous 
difference maps, though it is unclear why the difference in magnitude of the anomalous signals is so 
large. It is also important to note that there is also no discernable electron density surrounding the 
imidazole group, indicating that the histidine side chain is disordered. Conversely, analyzing the F284W 
mutant reveals a complete lack of anomalous signal at the allosteric site, and indeed the tryptophan ring is 
significantly larger than either histidine or phenylalanine. The electron density indicates that the 
tryptophan ring has moved towards the center of the allosteric pocket and serves to sterically occlude 
iodide from binding (Figure 33).  
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4.4 Kinetic characterization and anionic inhibition of PEPCK mutants  
Both the F284H and F284W rcPEPCK mutants were characterized in order to determine their new kinetic 
parameters for GTP/GDP nucleotide binding, due to the conformational changes of the P-loop as revealed 
by the structural data. The F284H mutant had a slight change in the KM for the nucleotides, while the 
F284W mutant had the most significant change, as expected. The KM for GDP in the PEP → OAA 
direction had increased to nearly 1 mM, an increase by a factor of 5 relative to the wildtype. Using these 
adjusted kinetic parameters, the chloride inhibition assays were repeated for both of the allosteric mutants 
in the forward and reverse directions of catalysis. Compared to the wildtype, inhibition of the F284H 
mutant decreased only slightly in both the forward and reverse directions, as can be seen by the change in 
KI (Table 16). This correlates to the structural data, where a decrease in anomalous signal demonstrated 
decreased anionic binding to the allosteric site of the F284H mutant. Interestingly, chloride inhibition of 
the F284W mutant was cut in half in the reverse direction compared to the wildtype (translated as an 
increase in KI by a factor of 2), while inhibition increased slightly in the forward direction of catalysis 
(Table 16). This does not correlate as well to the structural data as the histidine mutant did. From the 
aforementioned structural data, the F284W mutant showed no iodide binding to the allosteric site, and 
indeed the tryptophan ring appeared to occupy the allosteric pocket entirely. This discrepancy could likely 
be attributed to the use of two different halides between the kinetic and structural approaches. 
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4.5 Comparison of the kinetic and structural approaches 
The easiest way to examine the difference between chloride and iodide as anionic inhibitors was to repeat 
the kinetic inhibition assay on the wildtype enzyme, this time using iodide (Table 17). The resulting 
iodide inhibition constant (iodide KI = 33.8 mM) of the wildtype in the reverse direction of catalysis was 
significantly different than previously determined for chloride (chloride KI = 14.1 mM), and the data from 
the iodide re-plot shows a slight curvature, possibly indicating a partial inhibition via iodide. The kinetic 
inhibition assays show that chloride is roughly twice as potent as a competitive inhibitor than iodide. 
Aside from the obvious difference in electronegativity, due to chloride’s smaller ionic radius when 
compared to the iodide anion, steric hindrance would also play a lesser role in binding to the allosteric 
pocket. This could help explain why the kinetic data for the histidine mutant was nearly identical to that 
of the wildtype, while the structural data showed a much larger difference in anion binding. This likely 
applies to the tryptophan mutant as well, explaining why the kinetic data shows chloride inhibition of the 
F284W mutant, despite the structural data lacking any anomalous signal at the allosteric site.  
Another more difficult option would be to perform the structural approach using chloride as the inhibitor. 
However, like other more physiologically relevant atoms, chloride’s absorption edge (K edge of chloride 
is 4.4Å)40 is at a much longer wavelength that is unattainable at most beamlines.57  
It is also important to mention another key difference between the kinetic and structural approaches, 
namely the environment PEPCK is exposed to. To reiterate an integral point from earlier, the kinetic 
assays have high concentrations of substrates, metals and salts that are necessary for enzyme function. 
This includes the nucleotides that affect the conformation of the P-loop upon binding to the active site. In 
comparison, x-ray crystallographic conditions include the bare minimum of a buffer, precipitation agent, 
and manganese cations to induce nucleation. The kinetic and structural approaches by themselves, while 
providing insightful information, do not yield a complete picture. The combination of the two 
experimental methods act as supporting evidence to analyze allosteric regulation of PEPCK. 
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Chapter 5 Conclusions and Future Work 
Kinetic assays performed on the wildtype enzyme reinforced the fact that PEPCK activity is lower in the 
reverse direction of catalysis. Chloride inhibition assays demonstrated inhibition in the reverse direction 
to be significantly stronger than that of the forward direction by an order of magnitude. The resulting KI 
in the reverse direction determined the mM range of iodide concentration which would then be used in the 
subsequent crystal soaking experiments. WT rcPEPCK crystals were soaked over the 0 to 500 mM iodide 
concentration range, and the resulting anomalous signal found at the allosteric site was used to generate a 
binding isotherm, yielding a KD similar to that of the KI from the kinetic data. A combination of the 
kinetic and structural data provides evidence to suggest that binding to the allosteric site regulates enzyme 
activity in vivo, and ensures that PEPCK primarily catalyzes the reaction in the OAA→PEP direction 
needed for the gluconeogenic pathway despite being a thermodynamically reversible reaction. 
Analysis of the allosteric site reveals key residues that form the pocket. Mutagenesis of one of these 
residues, along with the complementary kinetic and structural approaches used for the wildtype, shows 
the role F284 plays in anion binding. It is hypothesized that non-covalent interactions with the protein 
backbone, and well as weak anion-π interactions with aromatic residues serve to bind anions to this 
pocket. Substituting for another amino acid, even another aromatic residue of similar size like histidine, 
affects anionic binding and therefore decreases the anionic inhibition of rcPEPCK. 
Structural comparisons between the wildtype and mutant enzyme variants demonstrate how binding to the 
allosteric site might affect nucleotide binding and therefore enzyme function. The close proximity of the 
allosteric site to that of the GTP/GDP nucleotide binding site causes any ligand binding at the allosteric 
site to directly inhibit enzyme activity by impeding nucleotide binding. In this way, anions that bind to the 
allosteric site can be classified as competitive inhibitors, since they alter apparent the KM and prevent the 
nucleotide from binding. Binding to the allosteric site causes the P-loop to become highly disordered, 
making it more difficult for the enzyme to adapt the correct conformation for nucleotide binding.  
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As with other reversible competitive inhibitors, inhibition can be overcome provided substrate is added at 
saturating conditions. Under high substrate concentrations, there is a greater probability that the 
nucleotide can bind to the active site, and the P-loop can adopt the appropriate conformation required for 
catalysis. The difference in affinity for the different nucleotides in the forward and reverse directions of 
catalysis can help explain why PEPCK inhibition is stronger in the reverse direction. The GTP nucleotide 
is preferred over GDP, as evidenced by the KM’s and binding affinities. Due to PEPCK’s greater affinity 
for the GTP, inhibition in the forward direction is relatively insignificant compared to that of the reverse 
direction. 
Combining a kinetic approach studying chloride inhibition, and a structural approach analyzing the 
binding of iodide via anomalous signal, we can hypothesize that the inhibition of PEPCK activity in the 
reverse direction can be mostly attributed to allosteric regulation. In this way, binding to the allosteric site 
is proposed to result in the unidirectional nature of the PEPCK-catalyzed reaction in higher eukaryotes, 
ensuring gluconeogenesis can occur.  
Further research is necessary to determine at what micromolar concentration of iodide will the active site 
begin to titrate in comparison to the millimolar scale of the allosteric site. X-ray diffraction at a 
specialized beamline with a longer wavelength would allow for the anomalous diffraction of chloride and 
a direct comparison with the chloride inhibition assays.57 Further kinetic assays on the wildtype should to 
be performed using other anions for a more detailed understanding of the cellular environment in vivo. 
Extended mutagenesis on the rat cytosolic enzyme and repeated experiments on other PEPCK isoforms 
could be done to observe the effects of anionic inhibition on enzymes involved in the key regulatory steps 
of metabolic pathways. 
 
 
 
 
 58 
 
References 
(1) Voet, D., Voet, J. G. (2011) Biochemistry 4th ed. John Wiley & Sons, Hoboken, New Jersey. 
(2) Chiba, Y., Kamikawa, R., Nakada-Tsukui, K., Saito-Nakano, Y., and Nozaki, T. (2015) Discovery of PP-type 
phosphoenolpyruvate carboxykinase genes in Eukaryotes and Bacteria. J. Biol. Chem. 290, 23960–23970. 
(3) Hanson, R. W., and Garber, A. J. (1972, October) Phosphoenolpyruvate carboxykinase. I. Its role in gluconeogenesis. Am. J. 
Clin. Nutr. 
(4) Forest, C., Tordjman, J., Glorian, M., Duplus, E., Chauvet, G., Quette, J., Beale, E. G., and Antoine, B. (2003) Fatty acid 
recycling in adipocytes: A role for glyceroneogenesis and phosphoenolpyruvate carboxykinase. Biochem. Soc. Trans. 31, 1125–
1129. 
(5) Tannen, R. L. (1978) Ammonia metabolism. Am. J. Physiol. 235, 265–277. 
(6) Granner, D., Andreone, T., Sasaki, K., and Beale, E. (1983) Inhibition of transcription of the phosphoenolpyruvate 
carboxykinase gene by insulin. Nature 305, 549–551. 
(7) O’Brien, R. M., Lucas, P. C., Forest, C. D., Magnuson, M. A., Granner, D. K. (1990) Identification of a sequence in the 
PEPCK gene that mediates a negative effect of insulin on trancription. Science (80-. ). 249, 533–537. 
(8) Liu, J., Park, E. A., Gurney, A. L., Roesler, W. J., and Hanson, R. W. (1991) Cyclic AMP induction of phosphoenolpyruvate 
carboxykinase (GTP) gene transcription is mediated by multiple promoter elements. J. Biol. Chem. 266, 19095–19102. 
(9) Xiong, Y., Lei, Q. Y., Zhao, S., and Guan, K. L. (2011) Regulation of glycolysis and gluconeogenesis by acetylation of PKM 
and PEPCK. Cold Spring Harb. Symp. Quant. Biol. 76, 285–289. 
(10) Latorre-Muro, P., Baeza, J., Armstrong, E. A., Hurtado-Guerrero, R., Corzana, F., Wu, L. E., Sinclair, D. A., Lopez-Buesa, 
P., Carrodeguas, J. A., Denu, J. M. (2018) Dynamic acetylation of cytosolic phosphoenolpyruvate carboxykinase toggles enzyme 
activity between gluconeogenic and anaplerotic reactions. Mol Cell. 71, 718–732. 
(11) Carlson, G. M., and Holyoak, T. (2009) Structural Insights into the Mechanism of Phosphoenolpyruvate Carboxykinase 
Catalysis. J. Biol. Chem. 284, 27037–27041. 
(12) Cui, D. S., Broom, A., McLeod, M. J., Meiering, E. M., and Holyoak, T. (2017) Asymmetric anchoring is required for 
efficient Ω-loop opening and closing in cytosolic phosphoenolpyruvate carboxykinase. Biochemistry 56, 2106–2115. 
(13) Case, C. L., and Mukhopadhyay, B. (2007) Kinetic characterization of recombinant human cytosolic phosphoenolpyruvate 
carboxykinase with and without a His10-tag. Biochim. Biophys. Acta - Gen. Subj. 1770, 1576–1584. 
(14) Johnson, K. A., and Goody, R. S. (2011) The original Michaelis constant: Translation of the 1913 Michaelis-Menten Paper. 
Biochemistry 50, 8264–8269. 
(15) Northrop, D. B. (1998) On the meaning of Km and V/K in enzyme kinetics. J. Chem. Educ. 75, 1153–1157. 
(16) Waldrop, G. L. (2009, January) A qualitative approach to enzyme inhibition. Biochem. Mol. Biol. Educ. 
(17) Monod, J. F. (1961) Teleonomic mechanisms in cellular metabolism, growth and differentiation. Cold Spring Harb. Symp. 
Quant. Biol. 26, 389–401. 
(18) Nussinov, R., and Tsai, C. J. (2015, February 1) Allostery without a conformational change? Revisiting the paradigm. Curr. 
Opin. Struct. Biol. Elsevier Ltd. 
(19) Gunasekaran, K., Ma, B., and Nussinov, R. (2004, November 15) Is allostery an intrinsic property of all dynamic proteins? 
Proteins Struct. Funct. Genet. 
(20) Fenton, A. W. (2008) Allostery: an illustrated definition for the “second secret of life.” Trends Biochem Sci 23, 420–425. 
(21) Stiffin, R. M., Sullivan, S. M., Carlson, G. M., and Holyoak, T. (2008) Differential inhibition of cytosolic PEPCK by 
substrate analogues. Kinetic and structural characterization of inhibitor recognition. Biochemistry 47, 2099–2109. 
(22) Izui, K., Matusda, Y., Kameshita, I., Katsuki, H., Woods, A. E. (1983) Phosphoenolpyruvate carboxylase of Escherichia 
coli. Inhibition by various analogs and homologs of phosphoenolpyruvate. J. Biochem. 94, 1789–1795. 
(23) Robinson, B. H., and Oei, J. (1975) 3-Mercaptopicolinic acid, a preferential inhibitor of the cytosolic phosphoenolpyruvate 
carboxykinase. FEBS Lett. 58, 12–15. 
 59 
 
(24) Makinen, A. L., and Nowak, T. (1983) 3-Mercaptopicolinate. A reversible active site inhibitor of avian liver 
phosphoenolpyruvate carboxykinase. J. Biol. Chem. 258, 11654–11662. 
(25) Balan, M. D., McLeod, M. J., Lotosky, W. R., Ghaly, M., and Holyoak, T. (2015) Inhibition and Allosteric Regulation of 
Monomeric Phosphoenolpyruvate Carboxykinase by 3-Mercaptopicolinic Acid. Biochemistry 54, 5878–5887. 
(26) Kretsinger, R. H., Uversky, V. N., Permyakov, E. A. (2013) Cellular Electrolyte Metabolism. Encycl. Met. Springer. 
(27) Frausto de Silva, J. J. R., Williams, R. J. P. (2001) Sodium, potassium, and chlorine osmotic control, electrolytic equilibria, 
and currents. Biol. Chem. Elem. Inorg. Chem. Life. Oxford University Press. 
(28) Krissinel, E., and Henrick, K. (2007) Inference of Macromolecular Assemblies from Crystalline State. J. Mol. Biol. 372, 
774–797. 
(29) Rossmann, M. G. (1990) The molecular replacement method. Acta Crystallogr. Sect. A 46, 73–82. 
(30) Hendrickson, W. A. (1985) Analysis of protein structure from diffraction measurement at multiple wavelengths. Trans. Am. 
Cryst. Assoc. 21, 11–21. 
(31) Smith, J. L. (1991) Determination of three-dimensional structure by multiwavelength anomalous diffraction. Curr. Opin. 
Struct. Biol. 1, 1002–1011. 
(32) Hendrickson, W. A. (2014) Anomalous diffraction in crystallographic phase evaluation. Q. Rev. Biophys. Cambridge 
University Press. 
(33) Rose, J. P., and Wang, B. C. (2016) SAD phasing: History, current impact and future opportunities. Arch. Biochem. Biophys. 
602, 80–94. 
(34) Sullivan, S. M., and Holyoak, T. (2007) Structures of rat cytosolic PEPCK: Insight into the mechanism of phosphorylation 
and decarboxylation of oxaloacetic acid. Biochemistry 46, 10078–10088. 
(35) Troy A. Johnson, T. H. (2012) The Ω‑Loop Lid Domain of Phosphoenolpyruvate Carboxykinase Is Essential for Catalytic 
Function. Biochemistry 51, 9547–9559. 
(36) Holyoak, T., Sullivan, S. M., and Nowak, T. (2006) Structural insights into the mechanism of PEPCK catalysis. 
Biochemistry 45, 8254–8263. 
(37) McNicholas, S., Potterton, E., Wilson, K. S., and Noble, M. E. M. (2011) Presenting your structures: The CCP4mg 
molecular-graphics software. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 386–394. 
(38) Johnson, T. A., McLeod, M. J., and Holyoak, T. (2016) Utilization of Substrate Intrinsic Binding Energy for Conformational 
Change and Catalytic Function in Phosphoenolpyruvate Carboxykinase. Biochemistry 55, 575–587. 
(39) Troy A. Johnson, T. H. (2010) Increasing the conformational entropy of the Ω-loop lid domain in PEPCK impairs catalysis 
and decreases catalytic fidelity. Biochemistry 49, 5176–5187. 
(40) Brennan, S., Cowan, P. L. (1992) A suite of programs for calculating x-ray absorption, reflection and diffraction 
performance for a variety of materials at arbitrary wavelengths. Rev. Sci. Instrum. 63, 850. 
(41) Dubnau, D. (1999) DNA Uptake in Bacteria. Annu. Rev. Microbiol. 53, 217–244. 
(42) Lorenz, M. G., Wackernagel, W. (1994) Bacterial Gene Transfer by Natural Genetic Transformation in the Environment. 
Microbiol. Rev. 58, 563–602. 
(43) Studier, F. W. (2005) Protein Production by Auto-Induction in High-Density Shaking Cultures. Protein Expr. Purif. 41, 
207–234. 
(44) Otwinowski, Z., Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzym. 276, 
307–326. 
(45) Collaborative Computational Project, Number 4. (1994) The CCP4 suite: programs for protein crystallography. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 50, 760–763. 
(46) Vagin, A., Teplyakov, A. (1997) MOLREP: an Automated Program for Molecular Replacement. J. Appl. Crystallogr. 30, 
1022–1025. 
(47) Emsley, P., Lohkamp, B., Scott, W. G., Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. Sect. D 
 60 
 
Biol. Crystallogr. 66, 486–501. 
(48) Tsai, C. S. (1967) Spontaneous decarboxylation of oxalacetic acid. Can. J. Chem. 45, 873–880. 
(49) Colombo, G., Carlson, G. M., and Lardy, H. A. (1981) Phosphoenolpyruvate Carboxykinase (Guanosine 5’-Triphosphate) 
from Rat Liver Cytosol. Dual-Cation Requirement for the Carboxylation Reaction. Biochemistry 20, 2749–2757. 
(50) Hebda, C. A., and Nowak, T. (1982) Phosphoenolpyruvate Carboxykinase. Mn2+ and Mn2+ Substrate Complexes 257, 
5515–5522. 
(51) Rocchio, S., Duman, R., El Omari, K., Mykhaylyk, V., Orr, C., Yan, Z., Salmon, L., Wagner, A., Bardwell, J. C. A., 
Horowitz, S. (2019) Identifying dynamic , partially occupied residues using anomalous scattering research papers. Acta 
Crystallogr. Sect. D Biol. Crystallogr. D75, 1084–1095. 
(52) Lewis, C. T., Seyer, J. M., and Carlson, G. M. (1989) Cysteine 288: An essential hyperreactive thiol of cytosolic 
phosphoenolpyruvate carboxykinase (GTP). J. Biol. Chem. 264, 27–33. 
(53) Jackson, M. R., Beahm, R., Duvvuru, S., Narasimhan, C., Wu, J., Wang, H. N., Philip, V. M., Hinde, R. J., and Howell, E. 
E. (2007) A preference for edgewise interactions between aromatic rings and carboxylate anions: The biological relevance of 
anion-quadrupole interactions. J. Phys. Chem. B 111, 8242–8249. 
(54) Berryman, O. B., Hof, F., Hynes, M. J., and Johnson, D. W. (2006) Anion-π interaction augments halide binding in solution. 
Chem. Commun. 1, 506–508. 
(55) Philip, V., Harris, J., Adams, R., Nguyen, D., Spiers, J., Baudry, J., Howell, E. E., and Hinde, R. J. (2011) A survey of 
aspartate-phenylalanine and glutamate-phenylalanine interactions in the protein data bank: Searching for anion-π pairs. 
Biochemistry 50, 2939–2950. 
(56) Chakravarty, S., Ung, A. R., Moore, B., Shore, J., and Alshamrani, M. (2018) A Comprehensive Analysis of Anion-
Quadrupole Interactions in Protein Structures. Biochemistry 57, 1852–1867. 
(57) Wagner, A., Duman, R., Henderson, K., and Mykhaylyk, V. (2016) In-vacuum long-wavelength macromolecular 
crystallography. Acta Crystallogr. Sect. D Struct. Biol. 72, 430–439. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
 
Appendix A: PEPCK Expression Vector Map 
 
Figure A: Polylinker map for the pE-SUMOstar expression vector. The WT rcPEPCK gene (accession # 
NM_198780.3; NP_942075.1) was cloned into the pE-SUMOstar vector as described previously, 
transformed into the BL21 E. coli protein expression cell line and stored at -80°C as a common cell stock.  
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Appendix B: Kinetic Characterization of WT rcPEPCK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B: Michaelis-Menten curves of the PEPCK-catalyzed reaction both in the OAA → PEP direction 
(top left), and the PEP → OAA direction (top right). Nucleotide curves of the PEPCK-catalyzed reaction 
both in the OAA → PEP direction (bottom left) and the PEP → OAA direction (bottom right).  
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Appendix C: Kinetic Inhibition of WT rcPEPCK by Chloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C1: WT rcPEPCK reverse direction kinetic inhibition assays under increasing chloride 
concentrations. 
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Figure C2: WT rcPEPCK forward direction kinetic inhibition assays under increasing chloride 
concentrations. 
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Appendix D: Reverse Direction Inhibition of WT rcPEPCK by Iodide 
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Figure D: WT rcPEPCK reverse direction kinetic inhibition assays under increasing iodide 
concentrations. 
WT rcPEPCK PEP Curve 0mM KI
[PEP] (µM)
0 1000 2000 3000 4000 5000
S
p
e
ci
fi
c 
A
ct
iv
ity
 (
µ
m
o
l/m
in
/m
g
)
0
2
4
6
8
10
12
14
 Vmax = 12.5
 Km = 258.8
WT rcPEPCK PEP Curve 10mM KI
[PEP] (µM)
0 1000 2000 3000 4000 5000
S
p
e
ci
fi
c 
A
ct
iv
ity
 (
µ
m
o
l/
m
in
/m
g
)
0
2
4
6
8
10
12
14
 Vmax = 9.3
 Km = 1028.5
WT rcPEPCK PEP Curve 25mM KI
[PEP] (µM)
0 1000 2000 3000 4000 5000
S
p
e
ci
fic
 A
ct
iv
ity
 (
µ
m
o
l/m
in
/m
g
)
0
2
4
6
8
10
12
14
 Vmax = 8.
 Km = 2081.1
WT rcPEPCK PEP Curve 50mM KI
[PEP] (µM)
0 1000 2000 3000 4000 5000
S
p
e
ci
fi
c 
A
ct
iv
ity
 (
µ
m
o
l/m
in
/m
g
)
0
2
4
6
8
10
12
14
 Vmax = 3.4
 Km = 1259.3
WT rcPEPCK PEP Curve 100mM KI
[PEP] (µM)
0 1000 2000 3000 4000 5000
S
p
e
ci
fic
 A
ct
iv
ity
 (
µ
m
o
l/m
in
/m
g
)
0
2
4
6
8
10
12
14
 Vmax = 1.7
 Km = 596.6
 66 
 
 
Appendix E: Kinetic Characterization of F284H and F284W rcPEPCK Mutants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure E: Kinetic characterization and determination of KM for the GTP and GDP nucleotides for the 
F284H (top) and F284W (bottom) rcPEPCK mutants. 
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Appendix F: Kinetic Inhibition of F284H rcPEPCK by Chloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F1: F284H rcPEPCK reverse direction kinetic inhibition assays under increasing chloride 
concentration. 
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Figure F2: F284H rcPEPCK forward direction kinetic inhibition assays under increasing chloride 
concentration. 
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Appendix G: Kinetic Inhibition of F284W rcPEPCK by Chloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure G1: F284W rcPEPCK reverse direction kinetic inhibition assays under increasing chloride 
concentration.  
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Figure G2: F284W rcPEPCK forward direction kinetic inhibition assays under increasing chloride 
concentration. 
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Appendix H: Kinetic parameters and competitive inhibition re-plots for wildtype and 
mutant rcPEPCK 
Table H1: Kinetic parameters of WT rcPEPCK and inhibition constant of KCl 
a) OAA + GTP → PEP + GDP + CO2 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 19.2 35.6 0.0521 1.854 
5 19.6 46.0 0.0510 2.347 
15 20.5 55.6 0.0488 2.712 
25 17.3 60.4 0.0578 3.491 
40 17 48.5 0.0588 2.853 
100 15.1 70.3 0.0662 4.656 
200 15.7 94.8 0.0637 6.038 
b) PEP + GDP + CO2 → OAA + GTP 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 12.9 206.3 0.0775 15.992 
5 12.1 205.1 0.0826 16.950 
15 10.1 225.7 0.0990 22.347 
25 9.9 304.7 0.1010 30.778 
40 9.4 376.0 0.1064 40.000 
100 8.9 862.5 0.1124 96.910 
 
 
 
Figure H1: Kinetic re-plots of chloride concentration and ratio of KM/Specific Activity for WT rcPEPCK. 
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Figure H2: Kinetic re-plots of chloride concentration and ratio of 1/Specific Activity for WT rcPEPCK. 
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Table H2: Kinetic parameters of F284H rcPEPCK and inhibition constant of KCl 
a) OAA + GTP → PEP + GDP + CO2 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 23.7 65.8 0.0422 2.776 
25 17.1 87.8 0.0585 5.135 
40 14.2 72.7 0.0704 5.120 
100 12.8 61.4 0.0781 4.797 
200 11.3 91.7 0.0885 8.115 
b) PEP + GDP + CO2 → OAA + GTP 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 13 236.4 0.0769 18.185 
5 12 234 0.0833 19.500 
15 12.1 290.7 0.0826 24.025 
25 11.8 361 0.0848 30.593 
40 10.2 450.3 0.0980 44.147 
100 9.7 913.6 0.1031 94.186 
200 8.9 1500 0.1124 168.539 
 
 
Figure H3: Kinetic re-plots of chloride concentration and ratio of KM/Specific Activity for F284H 
rcPEPCK 
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Figure H4: Kinetic re-plots of chloride concentration and ratio of 1/Specific Activity for F284H rcPEPCK. 
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Table H3: Kinetic parameters of F284W rcPEPCK and inhibition constant of KCl 
a) OAA + GTP → PEP + GDP + CO2 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 24.3 89.2 0.0412 3.671 
25 19.1 91.5 0.0524 4.791 
40 16.6 100.2 0.0602 6.036 
100 14.7 122.1 0.0680 8.306 
200 7.5 90.6 0.1333 12.080 
b) PEP + GDP + CO2 → OAA + GTP 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 3.4 126.6 0.2941 37.235 
15 3.2 148.4 0.3125 46.375 
25 3.1 144.7 0.3226 46.677 
40 3.1 245 0.3326 79.0323 
100 2.5 330.9 0.4000 132.360 
200 1.2 286 0.8333 238.333 
 
 
Figure H5: Kinetic re-plots of chloride concentration and ratio of KM/Specific Activity for F284W 
rcPEPCK. 
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Figure H6: Kinetic re-plots of chloride concentration and ratio of 1/Specific Activity for F284W rcPEPCK. 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 0.0004x + 0.0389
R² = 0.9452
0.0
0.2
0.4
0.6
0.8
1.0
0 50 100 150 200
1
/V
[KCl] (mM)
a) F284W Non-specific effects (OAA + GTP → PEP + GDP + CO2)
y = 0.0026x + 0.247
R² = 0.9098
0
0.2
0.4
0.6
0.8
1
0 50 100 150 200
1
/V
[KCl] (mM)
b) F284W Non-specific effects (PEP + GDP + CO2 → OAA + GTP)
 77 
 
Table H4: Kinetic parameters of WT rcPEPCK and inhibition constant of KI 
PEP + GDP + CO2 → OAA + GTP 
KCl (mM) Specific Activity 
(µmol/min/mg) 
KM (µM) 1/Specific Activity KM/Spec. Act. 
0 12.5 258.8 0.0800 20.704 
10 9.3 1028.5 0.1075 110.591 
25 8 2081.1 0.1250 260.138 
50 3.4 1259.3 0.2941 370.382 
100 1.7 596.6 0.5882 350.941 
 
 
 
 
 
 
 
 
 
 
 
Figure H7: Kinetic re-plots of iodide concentration and ratio of 1/Specific Activity for WT rcPEPCK. 
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Appendix I: Anomalous peak heights for iodide ions bound to WT, F284H and F284W 
rcPEPCK 
Table I1: Anomalous peak height raw data for WT rcPEPCK in e-/Å3 corresponding to crystals soaked 
from 10 to 500 mM KI. Iodides 1 and 2 are bound to the active site, while Iodide 3 represents the allosteric 
site. The remaining iodides have been numbered by decreasing peak height using the 500 mM KI structure 
as a reference.  
Iodide # 500 mM KI 250 mM KI 100 mM KI 50 mM KI 25 mM KI 10 mM KI 
Mn 13.7 11.26 11.56 15.8 17.28 16.23 
1 14.87 17.41 11.27 19.91 13.05 11.91 
2 11.71 8.33 7.72 5.79 6.93  
3 13.68 12.02 10.72 11.54 10.41 6.26 
4 10.95 10.11 6.24 9.05 6.66  
5 10.9 10.23 5.9    
6 9.05 9.61 11.43 6.63 5.55  
7 8.77 6.51  6.03   
8 8.32 6.53     
9 7.65 6.31     
10 7.15 6.02  5.6 5.9  
11 7.09      
12 6.98      
13 6.58 5.39     
14 6.56      
15 6.02      
16 5.99 5.84     
17 5.97 6.15     
18 5.29 5.11     
Table I2: Normalized anomalous peak height data for WT rcPEPCK in e-/Å3 corresponding to crystals 
soaked from 10 to 500 mM KI. Iodides 1 and 2 are bound to the active site, while Iodide 3 represents the 
allosteric site. The remaining iodides have been numbered by decreasing peak height using the 500 mM KI 
structure as a reference. The data was normalized by dividing peak height of the iodide by the peak height 
of the corresponding Mn (M1) cation. 
Iodide # 500 mM KI 250 mM KI 100 mM KI 50 mM KI 25 mM KI 10 mM KI 
Mn 1 1 1 1 1 1 
1 1.085 1.546 0.975 1.260 0.755 0.734 
2 0.855 0.740 0.668 0.366 0.401  
3 0.999 1.068 0.927 0.730 0.602 0.386 
4 0.799 0.898 0.540 0.573 0.385  
5 0.796 0.909 0.510    
6 0.661 0.853 0.989 0.420 0.321  
7 0.640 0.578  0.382   
8 0.607 0.580     
9 0.558 0.560     
10 0.522 0.535  0.354 0.341  
11 0.518      
12 0.510      
13 0.480 0.479     
14 0.479      
15 0.439      
16 0.437 0.519     
17 0.436 0.546     
18 0.386 0.454     
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Table I3: Anomalous peak heights for F284H and F284W rcPEPCK in e-/Å3 corresponding to crystals 
soaked from 10 to 500 mM KI. Iodides 1 and 2 are bound to the active site, while Iodide 3 represents the 
allosteric site. The remaining iodides have been numbered by decreasing peak height using the WT 500 
mM KI structure as a reference. The data was normalized by dividing peak height of the iodide by the peak 
height of the corresponding Mn (M1) cation. 
 Raw Data Normalized Data 
Iodide # F284H 250mM KI F284W 250mM KI F284H 250mM KI F284W250mM KI 
Mn 21.83 10.91 1 1 
1 11.49 6.66 0.526 0.610 
2 24.49 11.43 1.122 1.048 
3 5.73  0.262  
4 12.92 9.22 0.592 0.845 
5 10.83 6.2 0.496 0.568 
6 10.88 7.36 0.498 0.675 
7 7.33 7.69 0.336 0.705 
8     
9 6.53 4.42 0.299 0.405 
10     
11 5.99 5.86 0.274 0.537 
12 5.48 4.02 0.251 0.368 
13 6.03  0.276  
14     
15 5.68 4.73 0.260 0.434 
16 7.30 5.11 0.334 0.468 
17 7.03 4.12 0.322 0.378 
18 4.24  0.194  
19 7.05  0.323  
20 6.99 4.28 0.320 0.392 
21 5.58  0.256  
22 5.29 4.34 0.242 0.398 
23 5.00  0.229  
24 5.00  0.229  
25 4.66 4.29 0.213 0.393 
26  5.10  0.467 
27  5.29  0.485 
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Figure I1: Plot of normalized anomalous peak height for iodide 1 located in the active site. 
 
 
Figure I2: Plot of normalized anomalous peak height for iodide 2 located in the active site. 
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Figure I3: Plot of normalized anomalous peak height for iodide 3 located in the allosteric site. 
 
 
Figure I4: Plot of normalized anomalous peak height for iodide 4 located on the surface of PEPCK. 
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Figure I5: Plot of normalized anomalous peak height for iodide 6 located on the surface of PEPCK. 
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